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Parathyroid hormone-related protein (PTHrP) is a peptide hormone which, when 
abundantly produced by certain tumours, and released into the systemic circulation, 
stimulates via an endocrine-like pathway, bone resorption and renal calcium 
reabsorption, by interacting with a receptor that it shares with parathyroid hormone 
(PTH), the PTH/PTHrP type 1 receptor (PTH1R). PTHrP is undetectable in the 
circulation of normal subjects, but is produced in a paracrine/autocrine fashion during 
foetal and adult life by a number of normal cells and tissues, playing important roles 
in regulating cell proliferation, differentiation, and development. Tumours derived 
from the gastrointestinal tract that are not normally associated with hypercalcaemia, 
such as pancreatic adenocarcinoma, are known to express PTHrP. The expression of 
PTH1R has not been examined in pancreatic adenocarcinoma: there is no published 
literature detailing the evaluation of expression of PTHrP and PTH1R in 
gastrointestinal neuroendocrine tumours or hepatocellular carcinoma (HCC).
PTHrP and PTH1R protein was found, utilising immunohistochemistry, to be 
expressed by tumour cells in the majority of cases of a series of resection specimens 
of pancreatic adenocarcinoma and gastrointestinal neuroendocrine tumours, and all 
HCC studied. Furthermore, PTHrP and PTH1R were detected by western 
immunoblotting of cell lysates, and by immunohistochemistry in cells, from tumour 
cell lines derived from the above tumour types. Immunohistochemical expression of 
PTHrP, PTH1R, and the cell proliferation marker Ki67 was assessed and scored in 
tissue from normal liver, cirrhotic liver, putative neoplastic precursor lesions 
[macroregenerative (MRN) and dysplastic nodules (DN)], and HCCs. 
Immunopositivity for PTHrP correlated with the Ki67 score, and both sequentially 
increased from normal liver, to cirrhotic liver, to MRNs, to DNs, with a gradient of 
expression that peaked in tumour cells. Amino-terminal PTHrP (1-34) peptide was 
fluorescently labelled and observed to be taken up by HepG2 cells, confirming that 
these cells express functional PTH1R.
2The common expression of both PTHrP and PTH1R implies a possible 
autocrine/paracrine role for PTHrP/PTHIR in these tumours. The positive correlation 
in expression of PTHrP with Ki67, and sequential rise in the continuum of normal 
liver through to HCC, qualifies PTHrP as a likely candidate to influence hepatocyte 
and HCC growth. Agents that target the PTHrP/PTHIR system may have a 
therapeutic potential in these gastrointestinal malignancies that are frequently 
refractory to existing treatments.
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10Chapter 1  INTRODUCTION
Parathyroid hormone related peptide (PTHrP) was discovered in 1987 as the tumour 
product responsible for the most common paraneoplastic syndrome, humoral 
hypercalcaemia of malignancy. When abundantly produced by tumours and released 
into circulating blood, it stimulates, via an endocrine-like pathway, bone resorption 
and renal calcium reabsorption, by interacting with a receptor it shares with 
parathyroid hormone (PTH), called the type 1  PTH receptor (PTH1R).  The ability of 
PTH and PTHrP to bind to a single receptor is explained by limited sequence and 
conformational homologies within the first thirty-four N-terminal amino acids of the 
proteins. However, beyond these similarities, PTHrP is distinct from PTH in a number 
of ways: it is the product of a separate gene; the structure of the rest of the protein is 
dissimilar to that of PTH; it is a poly-hormone, comprising a family of distinct peptide 
hormones, arising from post-translational endoproteolytic cleavage of initial PTHrP 
translational products, each with their own physiological functions; and, in contrast to 
PTH, PTHrP is a paracrine factor expressed throughout the body at different times in 
foetal development or adult life. The precise function of PTHrP in most adult tissues 
has not been completely elucidated, but it has been reported to be important in growth 
and differentiation as well as cell proliferation and apoptosis.1  The conservation of the 
PTHrP gene and amino acid sequences among species suggests that the physiological 
role of PTHrP is important. This was confirmed by gene-knockout studies that 
demonstrated that a functional PTHrP gene is required for post-natal survival."
1.1  History
Hypercalcaemia in association with cancer was described in the 1920s, as methods for 
the measurement for serum calcium were introduced into clinical use. The initial 
series of patients emphasized the occurrence of hypercalcaemia in the context of 
skeletal metastases as the underlying cause of the malignancy-associated 
hypercalcaemia. However, in 1941, Dr. Fuller Albright presented the case of a patient 
with renal carcinoma, and only one skeletal metastasis, whose hypercalcaemia was
11accompanied by hypophosphataemia, which reversed when the tumour was removed. 
He speculated that PTH, or a related substance, was secreted by the tumour to produce 
an endocrine or ‘humoral’ hypercalcaemia.1 1 1  This observation was re-enforced later 
by Plimpton and Gelhom,lv reporting the occurrence of hypercalcaemia in a series of 
patients who had cancer with no apparent evidence of bone metastases.
By 1980, the clinical syndrome of humoral hypercalcaemia of malignancy (HHM) 
was well-defined biochemically. Patients with HHM were found to resemble patients 
with primary hyperparathyroidism, not only in that they both displayed 
hypercalcaemia, but that both groups also displayed elevations in nephrogenous 
adenosine 3’, 5’-cyclic monophosphate (cAMP) excretion, and reductions in renal 
tubular phosphate reabsorption. In contrast, patients with HHM had reduced 
circulating PTH, reductions in the activated form of vitamin D, 1, 25- 
dihydroxyvitamin D, and had higher fractional excretion of calcium. Further, in 
HHM, the rate of osteoclastic bone absorption is dramatically increased, whilst 
osteoblastic bone formation is uncoupled and decreased, compared to primary 
hyperparathyroidism where the rate of osteoclastic bone absorption is increased and 
coupled to the rate of osteoblastic bone formation. These observations indicated that 
the humoral factor responsible for the syndrome was not PTH, but a distinct hormone 
that was capable of interacting with the proximal tubular PTH receptor.
In 1987, using PTH-sensitive renal or osteoblast adenylyl cyclase assays as detection 
systems, three groups described the purification and N-terminal sequence of PTHrP 
and the molecular cloning of the corresponding complementary DNA.v,vl,vn By the 
early 1990s, the human,V U 1  rat,lx mousex and chickenxl PTHrP genes had been 
identified and described in structural terms. Synthetic and recombinant PTHrP had 
been shown to reproduce the HHM syndrome when infused into animals. In animals 
with hypercalcaemia caused by allografts of human tumours, the infusion of 
antibodies to PTHrP was shown to reverse the hypercalcaemia, and elevated 
circulating PTHrP concentrations were found by radioimmunoassay and 
immunoradiometric assays in patients with HHM, compared to normal subjects in 
whom circulating PTHrP is undetectable. This body of evidence established that 
PTHrP causes hypercalcaemia/1 1 ’X 1 U
12It is now widely accepted that PTHrP is the predominant cause of hypercalcaemia in 
patients with cancer. Among patients with solid tumours and hypercalcaemia, at least 
80 percent have increased serum concentrations of PTHrP,xlvand up to 20 percent of 
cancer patients have HHM.X V ,X V 1  These patients typically have squamous carcinomas 
(lung, oesophagus, cervix, head and neck), renal carcinomas, certain lymphomas, 
bladder carcinoma, and breast adenocarcinoma. When abundantly produced by such 
tumours and released into the systemic circulation, PTHrP stimulates via an 
endocrine-like pathway, bone resorption and renal calcium reabsorption, by 
interacting with the common so-called type 1 PTH receptor, PTH1R.
1.2  The PTHrP Gene
The human PTHrP gene is located on the short arm of chromosome 12. It consists of 
9 exons and contains at least 3 promoters and a silencer in the 5'- flanking region. The 
gene for PTH is located on an analogous region on the short arm of chromosome 11.
It is clear from the relatedness of the genes that flank the PTH and PTHrP genes, from 
the sequence homology of the amino-terminal sequences, and from the intron-exon 
organization of the two genes, that they arose from a common ancestral gene.
Through alternate splicing at the 5'- and 3'- ends, the human PTHrP gene yields an 
array of mRNA species (Figure 1). In particular, alternative 3'- splicing leads to the 
production of three separate mRNA classes, each encoding a protein with a distinct 
COOH-terminal. Furthermore, each contains instability motifs (AUUUA motif), 
involved in the rapid degradation of mRNAs, reminiscent of those found in early 
response genes which encode cytokines and growth factors.
13Figure 1  Structure of the Human PTHrP gene.
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The human PTHrP gene generates an array of mRNA species through alternate 
splicing at the 5'- and 3'- ends, represented by broken lines below the sequences, 
generating the production of 3 separate mRNA classes, each encoding PTHrP proteins 
with separate COOH-terminals. Introns are represented by a line. Promotors are 
represented by arrows above the sequences.
1.3  Regulation of PTHrP mRNA Expression
The physiological importance of alternative splicing of PTHrP remains unknown. 
Alternative splicing is an important mechanism in the regulation of gene expression, it 
increases the coding capacity of genes and enhances protein diversity. For example, 
alternative splicing of the calcitonin gene results in the expression of both calcitonin 
and calcitonin gene-related protein. These peptides have different functions, the 
former has a role in calcium haemostasis, the latter is a neurotransmitter and potent
14endogenous vasodilator, and both peptides are expressed in a tissue-specific 
manner.™1 ’  xvlllAdditionally, alternative splicing may give rise to mRNA variants with 
different half-lives. For example alternatively spliced insulin-like growth factor-I 
transcripts within the growth plate have differential mRNA stabilities that may be 
important in the regulation of chrondocyte growth.X 1 X
Tissue specific expression of one or more of the alternatively spliced PTHrP mRNA 
isoforms has been described. A number of groups have demonstrated that all iso forms 
are expressed in human HaCaT keratinocytes, but that the 139 iso form is 
predominant, whereas the 141 isoform alone is expressed in human lung tissue.xx 
Evidence of altered regulation of PTHrP mRNA has been demonstrated in different 
cancer cells, including human lung cancers, which express all PTHrP mRNA 
isoforms.xxl It is known that the expression of PTHrP is induced by a number of 
signalling molecules, including transforming growth factor-pl (TGF-pl) and 
epidermal growth factor (EGF).X X 1 1 ’xx This increased PTHrP mRNA expression has 
been shown to be due, in part, to the stabilization of PTHrP mRNA, and each isoform 
has a variable half-life that is differentially altered by cytokines. Hence, in cancer, 
changes in cell PTHrP mRNA expression may arise through differences in the 
cytokine milieu or alterations in cell function, which may contribute to the 
development of HHM or the rate of tumour growth or metastasis.™1 1  Lung cancers 
often express higher levels of TGF-pl,xx,v which may contribute to changes in PTHrP 
isoform expression between normal and cancerous tissue.
Increasing evidence indicates that PTHrP mRNA contains at least four CUG codons 
that have the potential to act as alternative translation sites downstream from the 
classical AUG start codon. Translation at these CUG sites appears to truncate and 
disrupt the function of the signal peptide, allowing translated peptide to remain within 
the cytosol.xxv The significance of this will be discussed later.
151.4  Translational Products and Post-Translational Processing
Translation of the PTHrP mRNA species give rise by alternate splicing to three 
related protein isoforms or initial translation products with distinct COOH-terminals. 
Each of the three isoforms contains a common 36 amino acid putative ‘prepro’ or 
signal sequence. Each isoform then contains 139 common amino acids: one 
terminates at amino acid 139; a second has an additional two amino acids, terminating 
at position 141; and in humans, a third extends an additional 34 amino acids to 
terminate at position 173 (Figure 2). Nascent PTHrP isoforms are then processed by 
members of the prohormone convertase family at multibasic endoproteolytic sites 
(multi-K/R) to at least three fragments: N-terminal PTHrP (1-36); a mid-region 
PTHrP (38-64); and, a C-terminal PTHrP (107-139).X X V 1  In humans, a further C- 
terminal species, PTHrP (141-173) is produced. The precise amino acid sequence of 
this fragment is unknown. The function of the signal peptide is to direct PTHrP, 
following translation on ribosomes, to the endoplasmic reticulum.xxv
Figure 2  Structure of the three initial PTHrP isoforms.
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This figure shows the three initial PTHrP isoforms arising from alternative splicing, 
posttranslational processing at multibasic endoproteolytic sites (multi-K/R), and the 
amino-terminal, mid-region and carboxy-terminal mature secretory forms of PTHrP, 
as they are understood at present. PTHrP (1-36) is the mature PTHrP species 
exhibiting PTH-like properties, not only in bone and kidney, but also in a number of 
other systems, including the cardiovascular system. This region contains the 1-13 
region in which 8 aminoacid are homologous to the analogous region in PTH. Note 
also the bipartite nuclear/nucleolar targeted sequence (NTS, also referred to as 
"NLS") in the 88- 106 region. From Clemens et al, 2001.1
16The N-terminal PTHrP (1-36) is structurally related to PTH. The region of sequence 
homology between the two peptides runs from amino acid 1 to amino acid 13. 
Although amino acids 14-34 of PTH and PTHrP share no primary sequence 
homology, these regions are highly similar in conformational terms, and compete with 
similar affinity to the PTH1R.
The 35-111 amino acid region is conserved among the four species for which the 
sequence is known (human, mouse, rat, and chicken), with the human and rat 
sequence differing by only two amino acids. This region contains a basic bipartite 
nuclear/nucleolar localization sequence (NLS) in its 88-107 region similar to the NLS 
in viral and mammalian transcription factors.
From amino acids 111-139, there is some degree of sequence conservation among 
species. The 141-173 region, which is derived from exon 5 of the human gene is not 
however homologous with any other peptide.xxvn This exon is not present in the rodent 
and chicken PTHrP gene. Therefore this region of the peptide appears to be human 
specific. In a recent study, a second tetrabasic KKKK (147-150) motif has been 
proven to determine nuclear/nucleolar localisation of PTHrP (1-173) in human 
chondrocytes.xxviii
1.5  Mature Secretory Peptides and Methods of Secretion
PTHrP isoforms may be secreted as intact peptides, or be processed into several 
mature secretory peptides. Processed secretory forms of peptide predominate over 
intact unprocessed peptide.xxlx Each peptide has its own biological properties and 
probably acts through distinct receptors.
One mature secretory form of PTHrP is PTHrP (1-36), which binds to the only 
characterised PTHrP receptor, the PTH1R. A midregion form of PTHrP that begins at 
amino acid 38 and has a COOH terminal at amino acid 94 has been identified, and a 
third peptide from amino acid 107 also exists. This latter form of PTHrP has been 
named ‘osteostatin’, to indicate the potency of synthetic PTHrP (107-139) as an 
inhibitor of osteoclastic bone resorption.xxx Work from several laboratories has 
identified a peptide recognised by antisera directed against this region of the peptide
17within cells, in conditioned medium, and in circulating serum from humans,X X X 1  
however the precise initial and final amino acid of the authentic form of osteostatin 
has not yet been identified.
Immunoassays against the human 140-173 sequence of PTHrP have also 
demonstrated the presence of a peptide with this immunoreactivity in plasma, tissue, 
and conditioned medium from normal cells and from cells transfected with PTHrP (1- 
173) cDNA. Again the precise origin and terminal amino acids of this peptide are 
unknown, and its physiological function is entirely speculative at present.
Other secretory peptide forms of PTHrP exist, which undergo further post- 
translational modification by glycosylation. Keratinocytes have been shown to secrete 
a heavily glycosylated form of the peptide that begins at the first amino acid (Ala-1), 
and extends for about 80 amino acids. The mass of the core protein is about 10 000 
kDa, whilst the mass of the glycosylated protein is approximately 18 000 kDa.xxxn The 
glycosylation is presumed to be O-glycosylation, since the PTHrP sequence contains 
no N-glycosylation consensus sequences, and is probably in the midregion of the 
peptide, since this region is rich in threonines and serines. The expression and release 
of a glycosylated form of full length PTHrP has also been found in coronary 
endothelial cells.xxxiii
PTHrP is unusual in that it is both a neuroendocrine peptide and a growth factor or 
cytokine. It is the product of a broad variety of neuroendocrine cell types (e.g. 
pancreatic islet cells, adrenal medullary cells), in which it is packaged into secretory 
granules, and undergoes extensive post-translational processing in a manner 
analogous to chromogranin A and somatostatin. However, like a cytokine or growth 
factor, PTHrP is processed and secreted in a constitutive fashion from cells which do 
not contain neuroendocrine secretory machinery such as vascular smooth muscle 
cells, osteoblasts and keratinocytes.xxxlv This duality of secretory mechanisms has not 
been described for other peptides.
181.6  PTHrP Receptors
1.6.a  The Type 1 PTH Receptor
The type 1 PTH Receptor, so called PTH1R, recognizes equally PTH (1-34) and 
PTHrP (1-36) and is expressed at high levels in bone and kidney, in which it mediates 
the classical effects of PTH and PTHrP, stimulating bone resorption and renal calcium 
reabsorption. PTH1R is also expressed at lower levels in a number of tissues in which 
it mediates a large array of non-traditional paracrine and autocrine functions and 
responds to locally produced PTHrP.
1.6.a.l  Receptor Structure
PTH1R is the only PTHrP receptor that has been characterized. It has been cloned in 
rat,xxxv  mouse,xxxvi>  opossum,xxxvii and human, xxxvili and is a G protein-coupled 
receptor (GPCR) with 7 membrane-spanning helixes (Figure 3).X X X 1 X  GPCRs are the 
largest family of integral membrane receptors, and mediate the action of numerous 
hormones, cytokines, sensory, and chemical signals. These receptors are classified in 
three major groups based on sequence homologies.xl PTH1R is a member of class B 
(Class II), which consists of peptide hormone and neuropeptide GPCRs, including 
receptors for secretin, calcitonin, and glucagon. The PTH1R receptor gene has been 
localised to human chromosome 3, and has a complex organisation with 14 exons 
encoding the putative receptor protein.xh Three 5' non-translated exons lie upstream 
from the signal peptide of the classical receptor. By using alternative transcription 
start sites in a tissue-specific manner, four alternatively spliced transcripts are 
transcribed with unique tissue distribution.^1 1
19Figure 3  Amino Acid Sequence and Predicted Topological Structure of 
Opossum PTH1R.
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Key: Arrow, Predicted cleavage site of the signal peptide. Gray circles, Conserved 
residues with the rat secretin receptor. Y, theoretical sites of N-glycosylation. [ ], 
boundaries of exon 2. From Vilardaga et al, 2001.1
1.6.  a. 2  PTH1R Activation and Signalling
PTH (1-34) or PTHrP (1-36) bind to PTH1R and signal through both adenylyl cyclase 
(AC) and phospholipase C (PLC). The significant sequence homology in the first 
thirteen amino acid residues of the two peptides reflects the importance of the N- 
terminal residues in PTH1R signalling. Between PTH and PTHrP, sequence 
homology decreases markedly in the 14-34 region, where only three amino acids are 
identical. For both PTH and PTHrP, the 15-34 region functions as the principal
20PTH1R binding domain, by interacting with the extracellular N-terminal domain of 
the PTH1R. These portions of the two peptides probably interact with the same or 
overlapping binding sites on the receptor, as the two fragments compete equally for 
binding with radiolabelled PTH (1-34) or PTHrP (1-36) to the PTHlR.xllY ’xlv These 
data also suggest that the two divergent receptor-binding domains of PTH and PTHrP 
adopt similar conformations.
The early N-terminal portions of each peptide contacts with the extracellular loops of 
transmembrane helixes 5 and 6 of the receptor, and this interaction is essential for AC 
stimulation. Adenylyl cyclase activation is thought to be responsible for most cellular 
responses to PTH and PTHrP. This pathway has been widely studied in a variety of 
cellular settings and typically elicits a robust and sensitive response to agonist ligands. 
In comparison, agonist efficacy and potency profiles observed in assays of the PLC 
pathway are generally lower.xlvi Phospholipase C seems to be selectively activated via 
binding of the PTHlR’s intracellular C-terminal tail to the PDZ-2 domain of 
Na(+)/H(+) exchanger regulatory factor (NHERF) 2 (Figure 4). PTH treatment of 
cells that express the NHERF2-PTH1R complex markedly activates PLC and inhibits 
AC through stimulation of inhibitory G proteins (G(i/o) proteins).xlvn Thus, it seems 
that NHERF-2 is a ‘switch’ that selects the signal pathways used by the activated 
PTHlR.xlvm  This may explain why PTH fragments with disabled or truncated N- 
noses, such as l-desamino-PTH(l-34), PTH-(3-34), and PTH-(13-34), can in some 
cells still strongly stimulate PLC and activate protein kinase C but not AC.xllx It may 
also be that the ability of these N-terminally truncated PTH fragments to activate the 
PLC/Ca  /PKCs mechanism in some cells but not others is a function of the 
availability of NHERF-2 adaptors.
21Figure 4 Illustration of PTH (1-34) binding and signalling to PTH1R.
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In this figure phospholipase C (PLC) is selectively activated via binding of the 
PTHlR’s intracellular C-terminal tail to Na(+)/H(+) exchanger regulatory factor 
(NHERF) 2. Adenylyl cyclase (AC) is inhibited through stimulation of inhibitory G 
proteins.
221.6.a.3  Desentisization and Internalization
The magnitude of hormone-induced physiological responses is normally tightly linked 
to the balance between GPCR signal generation and signal termination. The GPCR is 
activated by occupation which leads to biochemical events that uncouple the receptor 
from its cognate G-protein, producing a non-signalling, desensitized receptor. This is 
generally accompanied or followed by internalization, and depending on the particular 
receptor and cell, resensitization and receptor recycling to the cell membrane.1
Vilardaga et al reported the results of experiments using model HEK293 mammalian 
cells engineered to express human PTHlR.xlin The investigators showed that 
signalling by the PTH-PTH1R complex stops when the complex is endocytosed, 
which is rapid and occurs with a half-time of 3-5 minutes. Then, with a half-time of 2- 
4 hours, the PTH1R slowly reappears on the cell surface, ready to work again. This 
recycling requires a specific "recycling domain," which is located more distally than 
the "endocytosis domain" in the receptor's C-tail and is activated by the association of 
the phosphorylated receptor with the beta-arrestin-2 scaffolding protein. The PTH- 
PTHlR-beta-arrestin-2 complex is then targeted to a clathrin pit and carried into the 
cytoplasm in an endocytic vesicle. PTH is removed, PTH1R is dephosphorylated, 
functionally resensitized, and then put back on the cell surface, leaving the beta- 
arrestin-2 behind in the cytoplasm. The C-terminal tail of the receptor is 
phosphorylated by either second messenger-dependent kinases (AC/PLC) or by G- 
protein-coupled receptor kinase-2 (GRK2). Phosphorylation alone is insufficient to 
induce PTH1R internalization, but may produce a local concentration of negative 
charges that promotes binding to the positively charged recognition domain of an 
arrestin, thereby stabilizing the formation of the receptor-arrestin complex.1 '
PTH1R appears to exhibit ligand-specific inactivation and internalization, just as it 
exhibits ligand-specific activation. Sneddon et al using kidney distal convoluted 
tubule cells transfected with human PTHlR/enhanced green fluorescent protein fusion 
protein, employed quantitative, real-time fluorescence microscopy to analyse receptor 
internalization. In these cells, PTH (1-34) activated AC and PLC, and PTH1R 
endocytosis. Using PTHrP peptides truncated at the N or C terminus, they found that 
progressively N-truncated PTH peptides internalized the PTH1R without concomitant
23receptor activation. Conversely, a C-truncated PTH peptide efficiently activated the 
PTH1R but did not induce internalization.1 " Additionally, this study provided 
compelling evidence that GCPR activation and receptor endocytosis can be 
dissociated. This dissociation is likely to depend upon different intracellular 
conformations of the PTH1R. Alternatively phosphorylation of the C-terminal tail 
may induce a conformational change in arrestin that permits high-affmity interaction 
between the two proteins.
1.6.a. 4  PTH1R Nuclear Localisation
Immunoreactive PTH1R has been demonstrated within the nucleus of various tissues 
in a broad range of cell types.1 "1  Watson et al identified a nuclear localization 
sequence (NLS) between residues 446 and 473. By transfecting LLC-PK1 porcine 
kidney cells, which do not normally express PTH1R, with a vector containing the 
human wild-type PTH1R gene, they demonstrated that the transgene product got into 
the nucleus. When they transfected a vector containing a gene encoding a PTH1R 
without the NLS, however, the transgene product could only collect in a perinuclear 
ring. Thus, it seems that PTH1R has the ability to go directly to the nucleus instead of 
to the cell surface, and that PTHrP might act on nuclear function through binding to 
intranuclear PTH1R. Alternatively PTHrP may be internalized via receptor-mediated 
endocytosis, and be subsequently directed to the nucleus.
1.6.a  Other Receptors for PTHrP (1-36)
There is some evidence for the existence of a novel receptor for N-terminal PTHrP in 
keratinocytes, insulinoma cells, lymphocytes, and squamous cell carcinoma cells.llv,lv 
Both PTHrP (1-36) and PTH (1-34) have been proven to produce large increases in 
intracellular free calcium in keratinocytes and squamous cell carcinoma cell lines, but 
no increases in cyclic AMP, suggesting the existence of an alternate receptor for N- 
terminal PTH or PTHrP. Such a receptor has however not been conclusively 
identified.
Evidence for an additional receptor specific for PTHrP (1-36) has been observed in 
the rat supraoptic nucleus, in which it mediates a cyclic AMP-dependent stimulatory
24effect, on vasopressin release.lvi In these studies, PTH(l-34) was ineffective or unable 
to bind to the nucleus or displace bound PTHrP. Additionally a receptor that 
selectively binds PTHrP(l-36) and stimulates cyclic AMP has been identified in 
zebrafish.lvn,lvni Whether a mammalian homologue of this subtype of receptor exists, 
remains to be determined.
1.6.C  Receptors for Mid-regional and C-terminal PTHrP Species
The pro-hormone nature of PTHrP, with the documented existence of mid-region and 
carboxy-terminal secretory forms, strongly suggests the existence of additional 
receptors recognizing these mid region and C-terminal PTHrP peptides, as these 
peptides do not interact with the PTH1R and have no PTH-like activities. These 
receptors have not yet been identified.
1.7  An Intracrine Pathway for PTHrP
In addition to the classical autocrine/paracrine roles of PTHrP, for the most part, by 
binding via its N-terminal region [PTHrP(l-34)] to PTH1R,  PTHrP has been 
observed to have intracrine actions, entering the cell nucleus under the direction of a 
nuclear localisation signal (NLS). The latter concept first arose from the observation 
that the PTHrP sequence contains a NLS composed of multibasic amino acids in the 
88-106 region of the peptide, analogous to the prototypical nucleoplasmin NLS.llx 
This sequence also bears homology to sequences in human retroviruses shown to 
target regulatory proteins to the nucleus. A number of groups have shown that this 
sequence is necessary and sufficient for the nuclear localisation of PTHrP.lx’1 x 1   The 
mechanisms regarding the access, regulation and consequences of nuclear entry of 
PTHrP are areas of active research.
251.7.a  Mechanisms Underlying Translocation of PTHrP to the Nucleus
How does PTHrP, which undergoes extensive post-translational processing before 
secretion, enter the nucleus from the cytoplasm? Three possible mechanisms exist:  1) 
it is secreted and then re-enters the cell cytoplasm by endocytosis; 2) it does not enter 
the endoplasmic reticulum, but remains in the cytoplasm where it directly accesses the 
nuclear core; or, 3) it travels retrograde from the endoplasmic reticulum, to the 
cytoplasm, and then enters the nucleus (Figure 5). Evidence exists to support each of 
these possible mechanisms.
7.7. a. 1  Secretion and Endocytosis
The mechanism by which a secretory protein may gain access to the cytoplasm after 
secretion may involve endocytosis-dependent pathways. There are numerous 
examples of this mechanism for other peptide hormones, and cytokines, including 
angiogenin, angiotensin, and platelet-derived growth factor. Although endocytosis of 
PTH1R, with subsequent PTHrP transport and localisation to the nucleus has been 
demonstrated,1 x 1 1 ,1 x 1 1 1  other studies do not support this concept.lxlv
It is possible that a receptor distinct from the PTH1R mediates PTHrP endocytosis. 
Aarts et al demonstrated that full-length PTHrP (1-141), secreted from COS-1 kidney 
fibroblast cells transfected with PTHrP, can be endocytosed and subsequently targeted 
to the nucleus. This endocytosis was NLS-dependent, but did not require the 
PTHlR.lxv However, full-length PTHrP, which is the only secreted PTHrP species 
that contains the NLS, is a minor secretory form of PTHrP, making this pathway to 
the nucleus for PTHrP less likely. Alternatively, endocytosed PTHrP could reach the 
nucleus by binding to an intracellular form of the PTH1R. Joun et al described a novel 
splice variant of the PTH1R, which preferentially localized to the cytoplasm.xhl Such a 
pathway has also been described for fibroblast growth factor 2 (FGF-2).lxvl
1.7. a. 2  Alternative Translational Start Sites
As previously described, PTHrP mRNA contains at least four CUG codons within the 
signal peptide region that have the potential to serve as alternative translational start 
sites.lxvil,lxvm  Initiation of translation at these start sites appears to truncate the signal 
peptide, and disrupt its function. Thus the nascently translated PTHrP avoids entry
26into the endoplasmic reticulum, and remains in the cytoplasm where it is free to travel 
to the nucleus under the direction of the NLS. This scenario, which involves 
alternative initiation start site mechanisms at non-AUG codons, has been documented 
for FGF-2, where alternative initiation of FGF-2 mRNA occurs at three downstream 
CUG codons in addition to the conventional AUG start codon.lxix Therefore 
alternative initiation of translation results not only in the synthesis of the AUG- 
initiated form of FGF-2 that enters the endoplasmic reticulum, but also of three CUG 
-initiated FGF variants that remain in the nucleus and translocate to the nucleus, 
where they have a variety of biological effects.
1.7.a. 3  Retro2rade Trafficking from Endoplasmic Reticulum to the Nucleus 
Recent evidence suggests that secreted proteins can reverse-translocate from the 
endoplasmic reticulum to the cytoplasm. Misfolded proteins that would classically 
undergo degradation in the endoplasmic reticulum, can be retrogradely translocated 
from the endoplasmic reticulum to the cytoplasm, and then degraded by cytoplasmic 
ubiquitin-proteosomes.lxx PTHrP is a secretory protein that undergoes proteolysis 
through the ubiquitin-proteosome pathway,lxxi,kxlland so it is possible that PTHrP can 
be translocated back to the cytoplasm by specific endoplasmic reticulum sequestering 
proteins, and from there gain access to the nucleus without undergoing proteasomal 
degradation. The observation that the expression of a PTHrP construct that contains 
only the AUG initiating codon in CHO cells is targeted to both the secretory pathway 
and the nucleus is in accordance with this possibility.lxiv
27Figure 5  Potential pathways used by PTHrP to gain access to the cytoplasm
and nucleus.
a: Secreted PTHrP undergoes endocytosis at the cell surface in a 4 receptor’-mediated 
manner. Endocytosis could be mediated by PTH1R or a binding protein distinct from 
the receptor that recognises either the N-terminal domain or other regions of the 
PTHrP protein.
b: Initiation of translation of PTHrP mRNA downstream from the initiator methionine 
generates a signal peptide-truncated form of PTHrP. Such a protein localises within 
the cytoplasmic compartment because translocation through the membrane of the 
endoplasmic reticulum (ER) is now impaired.
c: PTHrP that has translocated into the ER lumen ‘dislocates’ back to the cytoplasm 
by the translocation unit or another transporter system (fc), and from there gains 
access to the nucleus.
(c)
(a)
281.7.b  Mechanisms Regulating PTHrP Entry to the Nucleus
PTHrP can shuttle in both directions, between the nucleus and the cytoplasm via 
distinct import and export nuclear receptors.lxx,n This movement is dependent upon 
the intregrity of microtubules, consistent with a direct role for the cytoskeleton in 
protein transport to the nucleus.lxxiv Nuclear import is regulated by phosphorlyation of 
the PTHrP threonine residue at amino acid position 85 by cyclin-dependent kinase 2 
p34,1 x 1 1 1  and is mediated almost exclusively by the saturable transport receptor 
importin p.lxxv A number of studies suggest that nuclear translocation of PTHrP is cell 
cycle dependent. Lam et al observed that PTHrP localises to the nucleus of cells in 
cultured HaCaT keratinocytes, at the Gi (quiescent) phase of the cell cycle, and was 
transported to the cytoplasm when cells divided.lxxvl In contrast Maasfelder et al 
reported that untransfected and PTHrP-overexpressing A10 vascular smooth muscle 
cells displayed immunoreactivity for PTHrP principally in the nuclei of cells that were 
in the process of division or completing cell division (G2 or M).lxxvu
1.7.C  Consequences of Nuclear Import of PTHrP
Endogenous PTHrP has been localized in situ to the dense fibrillar component of 
nucleoli, and the peptide has also been reported to bind homopolymeric and total 
cellular RNAs,lx x v 1 1 1  suggesting its potential involvement in regulating RNA 
metabolism. Several cellular effects have been associated with PTHrP nuclear import 
in vitro. It appears from available data that the physiological consequences of nuclear 
PTHrP entry vary from one cell type to another. Serum-deprived CFK2 chondrocytes 
and MCF-1 breast cancer cells over-expressing PTHrP with an intact NLS are 
protected from apoptosis.lx’lxxix In vascular smooth muscle cells (VSMC), the 
intracrine action of PTHrP is to activate cellular proliferation.lx x v 1 1  Interestingly, in 
these cells exogenous (i.e. paracrine/autocrine) PTHrP inhibits cell proliferation, 
indicating that the secreted and nuclear forms of PTHrP may have distinct, and at 
times, completely opposite effects on cellular function. PTHrP has also been 
demonstrated in prostate cells via an intracrine pathway, independent of the classical 
NLS, to produce production of IL-8.lxxx IL-8 is a potent angiogenic factor that 
contributes to tumourigenic activity in several cancers, and so PTHrP may mediate its 
effects on prostate cancer tumour progression via an intracrine pathway.
29In vivo evidence from gene targeting studies supports the dual function of PTHrP. 
Mice that are homozygous for PTHrP gene ablation die in the early post natal period 
from lethal defects associated with premature terminal differentiation and 
calcification of chondrocytes.lxxxi,lxxxn In contrast, animals that are homozygous for 
PTH1R gene ablation exhibit a more severe phenotype characterised by early 
embryonic lethality (day 14.5 of gestation)lxxxm  in association with abrupt 
cardiomyocyte death.lxxxiv The less severe phenotype seen in the PTHrP gene ablated 
mouse is unlikely to be explained by circulating PTH acting via PTH1R to 
compensate for PTHrP deficiency, as PTH expression does not normally occur in the 
developing embryo until day 15.5, whereas PTHrP expression is widespread at that 
time. The more severe phenotype seen in the PTH1R deficient mice may reflect the 
dual function of PTHrP. It is likely that normal embryonic development requires the 
coordinated activity between the amino-terminal PTHrP acting on the cell surface 
PTH1R (autocrine/paracrine pathway) and the intracellular formating at the nucleus 
(intracrine pathway).1 ™' In the absence of PTH1R, the unopposed nuclear events lead 
to severely dysregulated cell growth and/or differentiation, and therefore the early 
embryonic lethality of the receptor negative mutants. In contrast, in the absence of 
PTHrP, both receptor-mediated and nuclear activities are eliminated, leading to a 
more ‘coordinated’ cellular dysregulation, and hence less severe phenotype (FigureFigure 6  Illustration of the co-ordinated activity of the autocrine/paracrine 
and intracrine pathways of PTHrP.
In normal cells (wild type), the biological actions elicited by PTHrP require the 
coordinated activity between its (a) autocrine/paracrine pathway and (b) intracrine 
pathway.
In PTH1R deficient cells, extracellular signalling is absent, whereas the nuclear 
effects proceed unabated. This leads to severely dysregulated cell function and to the 
more severe phenotype of PTHlR-null animals.
In contrast, in ligand-deficient cells, both PTHrP signally pathways are abolished, 
leading to a more ‘coordinated’ functional disruption.
Wild Type  PTHIR-Null  PTHrP-Null
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\ \ \
Normal
Development
Severe
Impairment
Coordinated
Impairment
311.8  Physiological Effects of PTHrP
It is clear that PTHrP is produced in almost every tissue or organ in the body at some 
stage in foetal and adult development, and that PTHrP and PTH1R expression in early 
life is essential for normal development and survival. Insights into the variety of 
physiological roles of locally produced PTHrP as an autocrine/paracrine and 
intracrine factor have emerged from gene knock-out experiments and other 
approaches. Several common themes emerge from examining the physiological roles 
of PTHrP, namely: PTHrP may play more than one kind of role in a given tissue; 
PTHrP is a ‘pro-hormone’, and it is therefore possible for one secretory form of the 
peptide to have one effect whilst another secretory or intracrine form has another; in 
several tissues PTHrP has a role in transepithelial calcium transport; PTHrP appears 
to be a potent smooth muscle relaxant, the production of which can be induced by 
mechanical stretch of smooth muscle; PTHrP regulates growth, differentiation and 
development; and in many tissues the physiological roles of PTHrP are unknown.
32Table 1  Established and emerging physiological roles for PTHrP classified by
organ systems.
Organ
System
Functions of PTHrP
Cartilage Regulates endochondral bone development. Promotes chondrocyte proliferation 
and delays chondrocyte maturation and apoptosis.
The bipartite NLS in the 88-106 region targets PTHrP to the nucleus where it 
regulates cell differentiation and apoptosis via an intracrine pathway
A second NLS in the 147-150 region targets PTHrP to the nucleus where it 
determines intracrine regulatory effects of PTHrP (1-173) in human chondrocytes 
on PPi metabolism and matrix synthesis
Bone Stimulates bone resorption via its interaction with PTH1R.
PTHrP (107-139) (osteostatin) inhibits osteoclastic bone resorption via an as yet 
unidentified receptor.
Regulates Pi transport in osteogenic cells.
Ensures tooth eruption by resorption of alveolar bone, allowing passage of the 
newly developed tooth.
Skin and 
Hair follicles
Interacts with PTH1R to delay terminal differentiation of epidermal keratinocytes, 
keratinisation and apoptosis.
Promotes epidermal proliferation.
Decreases the number of hair follicles via epithelial-mesenchymal interactions.
Placenta Expressed by syncytiotrophoblast, intermediate trophoblasts, cytotrophoblasts, and 
amniotic epithelium.
Mid-region PTHrP interacts with an as yet unidentified receptor to maintain 
matemo-foetal gradients of calcium and magnesium.
Modulates trophoblastic growth and differentiation by interacting with calcium- 
binding proteins and calcium-sensing receptors.
Mammary gland 
and
Lactation
Necessary in epithelial-mesenchymal interactions during embryonic mammary 
development leading to nipple development and branching morphogenesis.
Induced by prolactin during lactation and released into the maternal circulating 
blood where it promotes calcium transport from blood to milk, increases 
mammary blood flow, and regulates maternal and neonate calcium-Pi metabolism.
Smooth muscle PTHrP is rapidly induced by vasoconstrictors and mechanical stretching and 
interacts with PTH1R to induce strong myorelaxant effects in a number of smooth 
muscle containing organs.
Blood vessels PTHrP and PTH1R are present in vascular smooth muscle cells (VSMC) and 
endothelial cells.
33Blood vessels 
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PTHrP decreases vascular tone and blood pressure and is believed to regulate 
regional and systemic haemodynamics.
PTHrP (1-36) binds to PTH1R to inhibit VSMC proliferation, whereas the 
bipartite NLS (88-106) targets PTHrP to the cell nucleus to stimulate cell 
proliferation and delay apoptosis.
Heart Regulates foetal heart development.
Exerts positive chronotropic effects and induces inotropic effects resulting from 
coronary dilatation.
Released by ventricular and atrial myocytes.
Kidney Possible role in kidney maturation and glomerular development. Expressed with 
PTH1R in renal tubules, glomeruli, intrarenal arterioles and arteries.
Mimics all PTH- effects on tubules by interacting with PTH1R.
Decreases renal vascular resistance, renal blood flow and glomerular filtration 
rate.
Exhibits a proliferative effect on tubular cells and mesangial cells.
Interacts directly with juxtaglomerular cells to stimulate renin release.
Lung Mediates lung development via an epithelial-mesenchymal paracrine loop. It is an 
autocrine inhibitor of growth and differentiation of alveolar type II cells in vivo 
and in vitro.
Uterus Upregulated by mechanical stretching and oestrogen. Potentiated by oestrogen, 
PTHrP relaxes uterus and vascular smooth muscle.
May regulate decidualisation of endometrial stromal cells.
May modulate implantation of the fertilised ovum and retention of the embryo. 
Inhibits oxytocin-stimulated activity during pregnancy and prevents preterm 
labour.
Gastrointestinal Expressed with PTH1R in many structuro-functional regions of the 
gastrointestinal tract.
Relaxes the smooth muscle layers by interacting with vasoactive intestinal factor. 
Expression increased in smooth muscle layers in response to distension.
Induces intestinal calcium transport.
Liver Possible foetal hepatic developmental factor regulating hepatogenesis that is 
extinguished postnatally.
Re-expressed during liver regeneration and endotoxic shock.
Pancreas Produced with PTH1R in beta cells in which it mediates intracellular calcium. 
Delays beta cell apoptotic death, increase beta cell growth and insulin secretion.
Parathyroid and Produced and released by the oxyphil cell lineage in adult thyroid and parathyroid 
glands.
34Thyroid glands Enhances low-calcium stimulated PTH secretion in vivo and in vitro.
Ovary and Testis PTHrP and PTH1R are expressed in the foetal and adult ovary and testis, but the 
function is unknown.
Prostate PTHrP but not PTH1R is expressed by the neuroendocrine cells of prostatic 
epithelium and is present in seminal plasma. Its role is unknown.
Central nervous 
system
Expressed with PTH1R in a number of areas.
Possible involvement with astrocyte differentiation.
Protects neurons from glutamate-induced exitotoxicity.
PTHrP gene is expressed under conditions that promote the survival of neurons. 
Displays a central pressor effect in conscious rats.
Adapted from Clemens et al, 2001.*™
1.9  Expression and Effect of PTHrP in Tumour Systems
HHM  is  the  most  common  paraneoplastic  syndrome  and  occurs  in  up  to  twenty 
percent of patients with solid tumours. PTHrP is also expressed by tumours that are 
not  associated  with  hypercalcaemia,  for  example  prostatic  adenocarcinoma,  and 
recent evidence suggests that in addition to its endocrine effects, PTHrP may have an 
autocrine/paracrine role, and intracrine effects in these tumour systems, in which the 
peptide is thought to influence tumour growth. Table 2 summaries the tumour types in 
which PTHrP is known to be expressed, and in some cases has an established effect 
on tumour cell growth, apoptosis or differentiation.
35Table 2  Tumours in which PTHrP expression has been established, and the
emerging effects of  PTHrP in these tumours.
Tissue Tumour Expression  of PTHrP and Possible Role References
Bone
Metastases
When  expressed  by  bone  metastases,  PTHrP  enhances  osteoblastic 
receptor  activation  of  NF-kB  ligand  (RANKL),  and  diminishes 
osteoprotegrin (OPG) expression; RANKL and OPG are key regulators 
of osteoclast formation and inhibition respectively.
Ixxxv, lxxxvi
Skin Expressed by squamous cell carcinomas (SCC) and in melanomas. 
Humoral hypercalcaemia of malignancy (HHM) occurs in patients with 
advanced melanoma and rarely in cutaneous SCC.
lxxxvii, lxxxviii,lxxxix
Breast HHM is common in patients with breast carcinoma.  Well  documented 
expression  in  the  majority  of breast  adenocarcinoma,  and  increased 
expression in bone  metastases,  which may provide  a  selective  growth 
advantage in bone.
xc,  xci,  xcii,  xxiii
Kidney Expressed in 95% of clear cell renal carcinomas, and via PTH1R is an 
essential growth and survival factor.
xciii, xciv, xcv
Lung HHM  is  common  in  squamous  cell  lung  carcinoma.  Common 
expression  in  all  types  of lung  cancer,  particularly  in  more  advanced, 
aggressive  tumours.  Exerts  protective  effects  against  apoptosis  and 
hence  may contribute  to  lung  cancer cell  survival  and promote  cancer 
progression. Serum PTHrP may predict survival.
xcvi, xcvii, xcviii
Gastrointestinal
tract
Expressed  by  colon  and  gastric  cancer.  Elevated  in  serum  of  some 
patients with gastroesophageal carcinoma.
xcix, c, ci
Liver/Biliary
tree
Expression  by  human  cholangiocarcinoma.  The  first  case  of 
malignancy-associated  hypercalcaemia  was  reported  in  a  patient  with 
cholangiocarcinoma.
cii, ciii
Exocrine
pancreas
Expressed by pancreatic adenocarcinoma.
civ
Endocrine
system
Expressed  by  pancreatic  endocrine  tumours  (PET).  There  are  several 
reported cases of HHM in patients with PET.
Expressed  in  parathyroid  adenomas,  medullary  thyroid  tumours, 
phaeochromocytomas,  adrenocortical  carcinomas,  and  pituitary 
tumours.
cv, cvi, cvii
Bladder Expressed by bladder carcinoma.
cviii
36Placenta PTHrP  is  produced  by  chorioangioma,  choriocarcinomas,  and 
hydatidiform moles.
cix, cx
Uterus Expressed by carcinoma of the uterine cervix.
cxi
Ovary Expressed by ovarian carcinoma in which HHM is relatively common.
cxii, cxiii
Prostate Commonly  expressed  by  prostate  carcinoma,  in  which  it  regulates 
tumour  progression,  especially  in  bone.  HHM  occurs  rarely  in  these 
patients.
cxiv, cxv
Central
Nervous
System
Expressed by  glial  tumours,  astrocytomas,  and  meningiomas.  In  glial 
tumours  high  expression  is  associated  with reduced  local  control  and 
survival after tumour irradiation.
cxvi, cxvii, cxviii
Immune
System
Expressed  in  lymphoma,  leukaemia,  and myeloma,  in which HHM  is 
common.
cxix, cxx
371.10  Rationale of Thesis
Expression of PTHrP protein by tumour cells has previously been described by 
Bouvet et al in resection specimens from normocalcaemic patients with pancreatic 
adenocarcinoma.c,v This group also detected PTHrP protein in western immunoblots 
of lysates from pancreatic adenocarcinoma cell lines. The expression of PTH1R by 
human pancreatic adenocarcinoma however has not previously been confirmed.
The purpose of the first part of this study was to examine by immunohistochemistry 
the expression of amino-terminal PTHrP and PTH1R, using a novel monoclonal 
antibody against the amino-terminal PTHrP [anti-PTHrP (1-10)] and an established 
anti-PTHIR antibody, in resection specimens from patients with well defined 
adenocarcinoma of the pancreas who were normocalcaemic pre-operatively. The 
disadvantage of using immunohistochemistry is that precise localization to a 
particular cell can be difficult and it is uncertain whether the cells detected by this 
method are the origin or target of the protein PTHrP, or rather have non-specifically 
absorbed the secreted protein. This question can be clarified by using in situ 
hybridization or real time polymerase chain reaction (RT-PCR) to detect PTHrP and 
PTH1R mRNA. However current available techniques are insensitive on paraffin- 
embedded archival tissue, poorly localizing, and time consuming. Acquisition, with 
informed patient consent, of new resection specimens of pancreatic adenocarcinoma 
for preservation in cryosection in sufficient numbers for this study, would have taken 
many years. This is because patients with adenocarcinoma of the pancreas usually 
present at an advanced stage, and therefore only a small proportion of patients go on 
to potentially curative surgery. Additionally new radiological techniques such as 
endoscopic ultrasonography and high resolution computer tomography have improved 
tumour staging to the extent that even fewer patients go to surgery. PTHrP and 
PTH1R mRNA was therefore not assessed in these tissues. Confirmation that PTHrP 
and PTH1R protein is expressed by tumour cells was assessed by performing 
immunohistochemistry on cytospin blocks of cultured cells, and western 
immunoblotting of whole cell lysates, from pancreatic adenocarcinoma cell lines.
Neuroendocrine tumours express a number of peptides, and peptide receptors, with 
associated humoral mechanisms. PTHrP is produced by beta-cells in the pancreatic
38islets, inducing cytosolic calcium responses, and regulating cell growth. In the second 
part of this study, the immunohistochemical expression of amino-terminal PTHrP and 
PTH1R was assessed in paraffin-embedded tumour resection specimens from patients 
with a variety of neuroendocrine tumours who did not have hypercalaemia. PTHrP 
and PTH1R expression in neuroendocrine tumour cell lines was investigated by 
immunohistochemistry and western immunoblotting. Further, any potential 
relationship between the expression of PTHrP/PTHIR and cellular proliferation was 
evaluated by measuring the immunohistochemical expression of nuclear Ki67 by 
tumour cells in the resection specimens, and correlating this with PTHrP/PTHIR 
expression.
Preliminary  work  suggested  that  PTHrP  is  expressed  in  human  hepatocellular 
carcinoma.C X X 1  Using the above monoclonal anti-PTHrP (1-10) antibody, PTHrP was 
detected  by  immunohistochemistry  in  hepatocellular  carcinoma  tumour  cells  in 
paraffin-embedded  resection  specimens.  The  third  part  of this  study  examines  the 
immunohistochemical expression of amino-terminal PTHrP and PTH1R in a series of 
cases  of  hepatocellular  carcinoma  resection  specimens  from  patients  who  were 
normocalcaemic.  PTHrP  and  PTH1R  protein  expression  was  also  assessed  by 
immunohistochemistry on cultured cells, and western immunoblotting of cell lysates, 
from hepatocellular carcinoma cell lines.
The observation that PTHrP is expressed in foetal liver, expressed at a low level or 
not at all in adult liver, and then ‘switched on’ in hepatocellular carcinoma suggests 
that in liver, as in a number of other tissues, PTHrP may play a role as a regulatory 
factor for hepatocyte growth and differentiation. As the majority of patients who 
develop hepatocellular carcinoma develop it on a background of cirrhosis of varying 
aetiology, this suggests that cirrhosis itself is a pre-neoplastic condition. If amino- 
terminal PTHrP and PTH1R play a paracrine/autocrine role in the progression and 
differentiation of hepatocellular carcinoma, then amino-terminal PTHrP and PTH1R 
would be expected to be expressed by hepatocytes in cirrhotic liver, and in 
premalignant liver nodules. Therefore the purpose of the fourth part of the study was 
to investigate by immunohistochemistry the expression of amino-terminal PTHrP and 
PTH1R in resection specimens from human normal liver, cirrhotic liver (regenerating 
nodules), macroregenerative nodules within cirrhotic liver, dysplastic nodules, which
39are putative hepatocellular carcinoma precursor lesions, and hepatocellular carcinoma. 
If the effect of amino-terminal PTHrP/PTHIR is to influence cell proliferation, then a 
correlation between it’s expression and the cell proliferation marker Ki67 would be 
expected. Proliferative activity in the tissues was therefore evaluated by measuring the 
immunohistochemical expression of nuclear Ki-67 antigen by hepatocytes or tumour 
cells in the same resection specimens. Any relationship between amino-terminal 
PTHrP/PTHIR expression and cellular proliferation was assessed.
Finally, functionality and cellular localisation of PTH1R expressed by the 
hepatocellullar carcinoma cell line HepG2 and the positive control cell line, prostatic 
adenocarcinoma PC3, was assessed by examining the uptake of fluorescently labelled 
amino-terminal PTHrP (1-34) by these cells.
The expression of both PTHrP and PTH1R by the tumour types studied may imply a 
possible autocrine/paracrine role for PTHrP in these tumours. A correlation between 
PTHrP/PTHIR expression and cell proliferation may also imply a regulatory role for 
PTHrP/PTHIR in tumour growth.
40Chapter 2  EXPRESSION OF PARATHYROID HORMONE- 
RELATED PEPTIDE AND THE PARATHYROID HORMONE 
TYPE 1 RECEPTOR IN PANCREATIC ADENOCARCINOMA.
2.1  Introduction
Parathyroid hormone-related peptide (PTHrP) is normally produced in the pancreatic 
beta cell, and can induce intracellular responses in cultured beta cells, indicating that 
these cells may have a paracrine/autocrine role involving PTHrP.llv In vivo studies in 
mice, in which PTHrP was targeted to and overexpressed in the pancreatic beta cell, 
have  shown  evidence  of growth-regulating  properties  of PTHrP.cxxn’  cxx,n  In  these 
animals there was  a progressive increase in pancreatic  cell mass,  islet number,  and 
beta cell number.
There  are  a  growing  number  of reports  of PTHrP-secreting  pancreatic  endocrine 
tumours causing hypercalcaemia.cxxlv’cxxv’C X X V 1 ’cxxvn’cxxvm  Hypercalcaemia associated 
with  exocrine pancreatic  tumour has  also been reported,  and  in  a  few  case  reports 
PTHrP  has  been  localized  by  immunohistochemistry  in  the  tumour.cxxlx’   cxxx’   cxxxl 
Bouvet et a lC IV  have shown that PTHrP is produced by human pancreatic cancer cell 
lines,  and  can  be  detected  by  immunohistochemistry  in  tumour  cells  of  human 
pancreatic adenocarcinoma tumour specimens in normocalcaemic patients. This group 
did not investigate the expression of the PTH/PTHrP type 1  receptor (PTH1R) by the 
tumours or tumour cell lines.
The aims of these experiments were:  1) to investigate by immunohistochemistry the 
expression  of PTHrP  and  its  corresponding  PTH1R  in  pancreatic  adenocarcinoma 
tumour resection specimens  from patients who were normocalcaemic  at the time of 
resection;  and  2)  to  investigate  by  immunohistochemistry  and  western 
immunoblotting the expression of PTHrP and PTH1R in pancreatic cancer cell lines.
412.2  Materials and Methods
2.2.a  Optimisation of Antibodies
2.2.a. 1  Anti-PTHrP
A novel mouse monoclonal anti-amino-terminal PTHrP antibody [PTHrP (1-10)] 
(Aphton Corporation, FL, USA) was optimised on paraffin-embedded tissues from 
regenerating liver and breast adenocarcinoma, which are well documented to express 
PTHrP cxxx11’cxxxin (Appendices I and II). Dilutional studies with this antibody showed 
that the optimal dilution for immunohistochemistry was 1:1000.
2.2. a. 2  Anti-PTHIR
Mouse monoclonal PTH1R antibody (Lab Vision Corporation, CA, USA), raised 
against amino acids 146-169 of the human PTH/PTHrP receptor, was optimised on 
paraffin-embedded tissue from the above cases of regenerating liver and breast 
adenocarcinoma (Appendix II). Breast adenocarcinoma is also well documented to 
express PTH1R.C X X X ,V  A dilution of 1:50 was the optimal concentration for these 
experiments.
2.2.b  Patient Tissue Specimens and Cell Lines
2.2. b. 1  Patient Tissue Specimens
Seventeen consecutive cases of well-characterised ductal pancreatic adenocarcinoma 
obtained at pancreatoduodenectomy between  1994 and 2003  were selected from the 
pathology archives of the Royal Free Hospital (Table 3). Tissue had been immediately 
formalin-fixed, routinely processed, and embedded in paraffin.
All of the patients had been normocalcaemic prior to  their procedures.  All patients 
had given consent for the use of the tissue for research, under ethical approval by the 
Royal Free Hospital ethics committee. The following clinicopathological details about
42the tumour case were collected: tumour differentiation, histological evidence of local, 
perineural and vascular invasion, and the presence of lymph node metastases. 
Sequential sections (5 pm thick) were cut with a microtome from the formalin-fixed, 
paraffin-embedded tissues,  mounted  on APES-coated  slides,  and  dried  overnight  at 
60°C.
2.2.b.2  Cell Lines
The  following  pancreatic  carcinoma  cells  lines  were  studied:  Panc-1,  BxPC3,  and 
AR42J. Panc-1 and BxPC3 are both human pancreatic carcinoma cell lines of ductular 
origin  (Panc-1  and  BxPC3  are  poorly  differentiated  and  moderately  differentiated 
tumour  cell  lines  respectively).cxxxv  AR42J  cells  are  derived  from  a  rat  pancreatic 
adenocarcinoma.G X X X V 1  All 3 cell lines were obtained from the European Collection of 
Animal  Cell  Cultures  (ECACC,  Porton Down,  UK).  Panc-1  cells  were  cultured  in 
Dulbecco’s  Modified  Eagles  Medium  (DMEM)  (Sigma  Chemical,  Poole,  UK) 
containing  10%  foetal  calf serum  (FCS)  (Sigma)  and  2mM  L-glutamine  (Sigma). 
BxPC3  and AR42J were cultured in RPMI-1640 medium  (Sigma Chemical,  Poole, 
UK) containing 10% FCS (Sigma) and 2mM glutamine (Sigma). All cells were grown 
at  37°C  in a humidified  95%  air -  5%  CO2 atmosphere,  and medium was  changed 
twice weekly.
The  human  prostate  cancer  cell  line  PC3,  which  is  known  to  express  and  secrete 
PTHrPcxxxvn and express a functional PTHlR,cxxxvln was chosen as a positive control 
cell  line.  PC3  cells  were  obtained  from  the  American  Type  Culture  Collection 
(ATCC, Manassas, VA, USA), and cultured in RPMI-1640 containing 10% FCS and 
2mM glutamine.
Cytospin blocks were prepared for each cell line from cells that had been grown to 
80% confluence. Sequential sections (5 pm thick) were cut with a microtome from the 
formalin-fixed, paraffin-embedded tissues, mounted on APES-coated slides, and dried 
overnight at 60°C.
432.2.c  Immunohistochemistry
Tissue sections and cell cytospin sections were dewaxed in xylene (Chemicon Europe, 
Limited, Hampshire, UK) for 10 minutes, rehydrated in 100% alcohol and then rinsed 
in double-distilled water for 5 minutes. Immunohistochemical localization of PTHrP 
and PTH1R was performed by the alkaline phosphatase anti-alkaline phosphatase 
(APAAP) method (Appendix III). All experiments were performed at room 
temperature, and were validated by the inclusion in each run of a positive control 
(breast adenocarcinoma) section for each antibody and parallel negative control 
sections for each tissue tested. Negative control sections were made by substitution of 
the primary antibody with normal mouse serum. For the anti-PTHrP antibody, 
specificity of staining was further validated by the inclusion of a parallel section of 
tissue that was incubated with a primary antibody solution of the same concentration 
of antibody (1 in 1000 dilution) that had been pre-absorbed overnight with excess 
immunizing peptide (0.25mg PTHrP [1-10]).
2.2.d  Evaluation of Immunohistochemistry Studies
Sections were examined by light microscopy and scored by two independent 
observers. Cells were considered positively stained if cytoplasm, cell membrane, or 
nucleus was distinctly coloured compared with background, and if staining was absent 
from adjacent negative control sections.
For tumour sections and cell lines the intensity of staining was compared to that of the 
positive control for each antibody in each run. The intensity of staining was graded on 
a scale from 0 to 3 where, 0 indicated no staining; 1  indicated weak intensity of 
staining; 2, moderately intense staining; and 3, most intense staining. Sections were 
also given a score to grade the extent of staining, such that less that 25% positive cells 
= 1; 25-75% cells = 2; and more than 75% = 3. To obtain a numerical score, the 
intensity of staining was multiplied by the number of cells stained. This scoring 
system has been previously validated.C X X X U 1 ’cxxx,x Scores were used to separate the
44positive results into weak (1 and 2), moderate (3 and 4), and strong (6 and 9) 
categories.
2.2.e  Statistical Methods
Statistical analyses were performed using the Spearman rank correlation test, and the 
Mann-Whitney U non-parametric test for group differences. These were carried out 
using SPSS, version 11.0 (2001) (SPSS Inc., Chicago, USA). A P value of less than 
0.05 was considered to be statistically significant.
2.2.f  Western Immunoblotting
2.2.f.l  Preparation of cell lysates
Cells from the following cell lines were cultured in T-75 flasks: AR42J, BxPC3, 
Panc-1 and PC3. After washing with phosphate buffered saline (PBS) the cells were 
lysed in 800mM Tris buffer pH 6.8 containing 5% SDS and lOOmM phenylmethyl- 
sulfonyl fluoride. Protein content in the lysates was measured using a modified Lowry 
assay (Bio-Rad DC Protein Assay, Bio-Rad, CA, USA).
2.2.f2  Immunoblotting
Prepared lysates were boiled for 4 minutes with bromophenol blue and 30% glycerol. 
A volume of lysate corresponding to 10 pg of protein was loaded onto Laemmli SDS- 
polyacrylamide gels. Western blotting conditions and gels were optimized in order to 
detect bands below 6kD [PTHrP (1-34): Mr = 4017.61]. The gels were run at 100V in 
Tris-glycine buffer containing 0.1% SDS until the dye front reached the bottom of the 
gel. A low molecular weight range protein standard (Sigma Marker™, Sigma) was 
also loaded onto each gel. After separation, the proteins were electrotransferred in 
cooled transfer buffer to nitrocellulose at 250mA (100-120V) over 60 minutes. The 
membranes were blocked in PBS containing 5% bovine serum albumin (BSA) 
(Sigma) and 0.1% Tween 20 (Lab Vision Corporation, CA, USA) for 30 minutes at 
room temperature, and then incubated with primary antibody overnight at 4°C.
After three 5- minute washes in PBS/0.1% Tween 20, the membranes were incubated 
with goat anti-rabbit/mouse biotin (DAKO, Copenhagen, Denmark) at a 1:200
45dilution in the same buffer for 1 hour. The membranes were washed again three times 
in PBS/0.1% Tween 20 and then incubated with streptavidin/biotin-peroxidase 
complex (1:200 dilution, DAKO) for 30 minutes. Peroxidase activity was revealed 
using a diamino-benzidine/hydrogen peroxide solution (Vector VIP, Vector 
Laboratories, UK).
2.2.  f.3  Primary Antibodies
The following primary antibodies were used:
PTHrP (1-341 antibody
Rabbit polyclonal antibody [Bachem (UK) Ltd., Merseyside, UK], raised against the 
amino-terminal sequence of PTHrP, was used at a dilution of 1  in 200 in PBS. As an 
additional control, 15pg of immunizing PTHrP peptide [Bachem (UK) Ltd] was 
loaded and included in each run. The results were validated by the inclusion of 
parallel blots which had been incubated with a primary antibody solution of the same 
concentration of antibody that had been pre-absorbed overnight with excess 
immunizing peptide [0.1 mg PTHrP (1-34)]. Bands were considered to represent 
PTHrP peptides only if they were abolished or significantly attenuated by pre­
absorption.
PTHrP (38-64) antibody
Mouse monoclonal antibody (Oncogene Research Products, CA, USA), raised against 
an amino acid sequence within the mid-fragment PTHrP, was used at a concentration 
of 5pg/ml. The immunizing peptide was not commercially available.
PTH1R antibody
The following amendments were made prior to immunoblotting with this antibody 
which was used at a dilution of 1  in 10: cell lysates were incubated with bromophenol 
blue and 30% glycerol at room temperature; 10% SDS-polyacrylamide gels were used 
with Full Range Rainbow™ (Amersham Biosciences UK Limited, Buckinghamshire, 
UK) recombinant protein molecular weight markers.
462.3  Results
2.3.a  Immunohistochemistry on Patient Tissue Sections and Cell Lines
2.3. a. 1  Patient Tissue Sections 
PTHrP
Of the 17 cases of pancreatic adenocarcinoma tested, 16 showed positive tumour cell 
staining for PTHrP [median score 6 (range 0-6)] (Table 3). Staining of tumour cells 
was predominantly cytoplasmic, and occurred in a background of stromal fibrosis 
typical of pancreatic adenocarcinoma (Figure 7). In some of the tumour resection 
specimens, nuclear staining in tumour cells was also seen (case numbers 6, 10, and 
17). As expected, there was positive staining for PTHrP in adjacent normal pancreatic 
islet cells, and some normal exocrine ducts and ductules.cvl Negative controls (no 
primary antibody and competition with excess PTHrP) revealed no positive staining.
PTH1R
In 15 of the 17 pancreatic adenocarcinoma specimens, tumour cells showed positive 
cytoplasmic staining for PTH1R [median score 3 (range 0-6)] (Table 3; Figure 8). 
There was variable cytoplasmic staining for PTH1R in adjacent normal pancreatic 
islet cells and ducts. Nuclear staining was also observed in some of the tumour 
resection specimens (case numbers 6, 10, and 17). All staining for PTH1R was 
abolished by substitution of normal mouse serum for primary antibody.
47Figure 7  Immunohistochemistry  showing  positive  tumour  cell  staining  for
PTHrP in resection specimens of human pancreatic adenocarcinoma
The  images  are  from  four  different  cases  of  pancreatic  adenocarcinoma,  and  are 
representative  of the  results  obtained.  Positive  staining  appears  as  a  red  precipitate 
Figures  (a),  (b),  and  (c)  demonstrate  positive  cytoplasmic  staining  (photographed  at 
magnification  xlOO).  Figure  (d)  shows  positive  nuclear  and  patchy  cytoplasmic 
staining (photographed at magnification x200).
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Figure 8  Immunohistochemistry  showing  positive  tumour  cell  staining  for
PTH1R in resection specimens of human pancreatic adenocarcinoma
The  images are  from  the  same four cases  of pancreatic  adenocarcinoma  as  shown  in 
Figure  7,  and  are representative of the results obtained  Positive staining appears as a 
red  precipitate  Figure  (a)  shows  positive  cytoplasmic  and  membranous  staining 
(Photographed  at  magnification xlOO).  Figures (b) and  (c)  show positive cytoplasmic 
staining (photographed at magnification xlOO).  Figure (d)  shows positive nuclear and 
cytoplasmic staining (photographed at magnification x200)I  »>'  'Table 3  Histological details and immunohistological expression of  PTHrP and
PTH1R in specimens from 17 patients with pancreatic adenocarcinoma.
Case
No.
Age
(years)
Sex Differentiation 
of Tumour
Tumour invasion Tum our cell 
staining
Local
Tissue Vascular Perineural
Lymph
node
PTHrP
(0-9)
PTH1R
(0-9)
1 56 M
in situ duct 
carcinoma no no no no 6 6
2 61 F moderate yes yes yes no 6 4
3 68 M moderate yes yes yes no 3 4
4 62 M moderate yes no yes yes 1 0
5 74 F well yes no yes no 4 2
6 65 M moderate yes yes yes yes 4 6
7 64 M
variable
(moderate/well) multifocal yes yes no 2 0
8 48 F well yes yes yes yes 1 1
9 81 M well yes no no yes 6 3
10 74 F moderate yes yes yes yes 6 4
11 65 F well yes no yes no 6 4
12 64 M well yes no yes yes 6 2
13 47 F moderate yes no yes yes 6 3
14 54 F moderate yes no yes no 6 4
15 69 F moderate yes yes yes no 6 4
16 45 M moderate yes yes yes yes 0 3
17 55 M moderate yes yes yes no 4 3
Legend: M, male; F, female
In 14 of the 17 cases of pancreatic carcinoma, there was positive staining for both 
PTHrP and PTH1R. There was a positive correlation between the tumour staining 
scores for PTHrP and for PTH1R (R = 0.527, p = 0.025). There was no significant 
difference between the staining scores for either PTHrP or PTH1R in the well
54differentiated tumours compared to the moderately differentiated tumours (there were 
no poorly differentiated tumours in this series). There was no significant difference in 
tumour staining for either PTHrP or PTH1R in tumours with or without histological 
evidence of local, vascular or perineural invasion.
2.3.  a. 2  Cell Lines
Preliminary studies on PC3 cell cytospin sections showed strong cytoplasmic staining 
for PTHrP in all cells (score 9). Nuclear staining was also seen in 5-10% of cells. 
Positive staining of moderate intensity was observed for PTH1R in the cytoplasm and 
membrane of all cells (score 6).
PTHrP
PTHrP was localised by immunohistochemical staining in the cytoplasm of all 3 cell 
lines tested (Table 4, Figure 11). Nuclear staining was observed in 1-5% of BxPC3 
cells (Figure 9). Preabsorption of the antibody with the immunizing peptide abolished 
all staining.
PTH1R
PTH1R was localised to the membrane and cytoplasm in BxPC3 and Panc-1 cells 
(Table 4). Nuclear staining for PTH1R was also seen in 1% of BxPC3 cells (Figure 
10). There was no staining for PTH1R in AR42J cells (Figure 11). All staining for 
PTH1R was abolished by substitution of normal mouse serum for primary antibody.
55Figure  9  Immunohistochemistry showing nuclear and  cytoplasmic  staining for 
FTH rPinthe human pancreatic carcinoma cell line  BxPC3  (original magnification x 
100)
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Figure  10  Immunohistochemistry showing  cytoplasmic  and nuclear staining for 
PT H lR inthe human pancreatic  carcinoma cell line  BxPC3  (original  magnification x 
100)Figure 11  Immunohistochemistry showing cytoplasmic staining for PTHrP 
(figure a) and no staining for PTH1R (figure b) in cell cytospins of the rat pancreatic 
cell line AR42J. (Original magnification x 200)
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Table 4  Immunohistochemical expression of PTHrP and PTH1R in the
pancreatic cell lines studied.
Cell line
Intensity and location of 
immunostaining for 
PTHrP
Intensity and location of 
immunostaining for 
PTH1R
AR42J 9  (C) 0
BxPC3 6  (C&N) 6  (N, C, M)
Panc-1 6  (C) 4  (C & M)
Legend: C = cytoplasmic, M = membranous, N = nuclear
The immunoreactive product was scored between 0 and 9. To obtain a numerical 
score, the intensity of staining (scored from 0 to 3) was multiplied by the percentage 
of cells stained (scored from 0 to 3).
572.3.b  Western Immunoblotting
PTHrP (1-34)
A distinct band that was abolished by pre-absorption was present for the control 
PTHrP (1-34) peptide at approximately 5 kDa. Distinct bands that were abolished by 
pre-absorption were present in the PC3, AR42J and Panc-1 cell lysates at 17 kDa, 35 
kDa, and 45 kDa, and in the BxPC3 cell lysate at 35 kDa and 45 kDa (Figure 12a).
PTHrP (38-64)
A distinct two-band pattern with proteins at 15- and 50 kDa was noted in the PC3 and 
AR42J lysates, and at 35 kDa and 50 kDa in the Panc-1 and BxPC3 lysates.
PTH1R
Bands were seen at 60 kDa in the PC3, Panc-1, and BxPC3 cell lines. Bands at 45 
kDa were seen in AR42J, Panc-1, and PC3. Additional bands at 80- and 160 kDa were 
seen in the PC3 lysate.
58Figure 12  Western immunoblots for PTHrP (1-34) and PTH1R on whole cell 
lysates from pancreatic adenocarcinoma cell lines and prostate adenocarcinoma cell 
line PC3.
Figure (a) is a representative immunoblot for PTHrP (1-34). Bands that are attenuated 
by pre-absorption are seen at 17 kDa, 35 kDa, and 45 kDa in the PC3, AR42J and 
Panc-1 cell lysates, and in the BxPC3 cell lysate at 35 kDa and 45 kDa.
Non-preabsorbed immunoblot
kDa  PC3  AR42J  Panc-1  BxPC3
Preabsorbed  (a)
PC3  AR42J  Panel  BxPC3
Figure (b) is a representative immunoblot for PTH1R. Distinct bands are seen at 60 
kDa in the PC3, Panc-1, and BxPC3 cell lines. A band at 45 kDa only is seen in the 
rat adenocarcinoma cell line AR42J. This 45 kDa band is also present in the PC3 and 
Panc-1 lysate.
AR42J
(b )
592.4  Conclusions
These results show that there is protein expression of PTHrP in all 3 pancreatic cancer 
cell lines and in the majority of the human pancreatic adenocarcinoma specimens that 
were studied. PTH1R protein is also highly expressed in human pancreatic 
adenocarcinoma tumour cells, but was not detected by immunohistochemistry or 
western immunoblotting in the rat adenocarcinoma cell line AR42J.
The 15-17 kDa protein bands detected by immunohistochemistry on the Western blots 
are appropriate sizes for PTHrP (1-139) and PTHrP (1-141) molecules (Mw 16-20 
kDa).cxl The anti-PTHrP antibodies also detected peptides of approximately 35 kDa 
and 45-50 kDa, which may represent polymerisation of PTHrP molecules, or possibly 
represent glycosylated mature PTHrP, providing indirect evidence for PTHrP 
processing. Bouvet et alclv reported that they obtained 17 kDa, 34 kDa, and 44 kDa 
bands of immunoreactive PTHrP in BxPC3 and Panc-1 cell lysates, among other 
pancreatic cancer cell lines tested, using a monoclonal antibody to PTHrP (109-141). 
Other groups have also reported obtaining bands of similar sizes on western blots of 
proteins extracted from different tissues using rabbit polyclonal anti-PTHrP (1-34) 
and PTHrP (56-86).cx1, cxh Schliiter et al, using the same monoclonal PTHrP (38-64) 
antibody used in this study to immunoprecipitate PTHrP from rat coronary endothelial 
cells, also detected a single protein band with an apparent molecular weight of about 
50 kDa.cxln Utilising a digoxigenin-glycan detection assay, indicating glycosylation of 
proteins, this group confirmed that the higher molecular weight PTHrP was modified 
by glycosylation, and postulated that glycosylation was a post-translational 
modification. They demonstrated that this glycosylated PTHrP was biologically 
active, in that it exerted a positive contractile effect on cardiomyocytes, with a higher 
potency than synthetic PTHrP (1-34).
Smaller bands, of appropriate size for amino-terminal and mid-fragment daughter 
species, were not detected on the western blots of the cell lysates. This may be 
because the smaller peptides were degraded during processing of the whole cell 
lysates, or because cleavage of mature PTHrP by members of the prohormone 
convertase family into daughter peptides does not occur in these tumour cells.
60Endoprotease cleavage of mature PTHrP may not occur in pancreatic adenocarcinoma 
tumour cells either to the absence of specific endoproteases in these de-differentiated 
cells, or because during PTHrP translation, amino acid substitution occurs one at of 
the cleavage sites, for example the monobasic Arg37, which is then not recognised by 
the endoprotease.
The 60 kDa protein bands obtained with the anti-PTHIR antibody are an appropriate 
size for non-glycosylated PTH1R. The 80 kDa band observed in the control cell line 
PC3 is an appropriate size for the glycosylated PTH1R,cxlm  and has been obtained by 
other groups using this antibody.cxvl  The 160 kDa band is likely to represent a dimer 
of the glycosylated receptor. A 45 kDa band has also been described using an anti- 
PTHIR antibody raised against a peptide sequence in the extracellular N-terminal 
region of the receptor,cxh and may represent a truncated form of the receptor.
The dual expression of PTHrP and PTH1R in human pancreatic tumour cell lines, and 
in tumour resection specimens, and the significant positive correlation between the 
intensity of the staining for PTHrP and for PTH1R suggests that an autocrine and/or 
paracrine loop may exist for PTHrP, acting via the PTH1R, in these tumours. 
Moreover, positive nuclear staining for PTHrP and PTH1R was seen 1-5% of BxPC3 
cells, and in tumour cells in some of the resection specimens. PTHrP staining was 
observed principally in a diffuse nuclear pattern, as observed by other groups.lx1’lxxvn’  
lxxx  suggests that either nucleolar translocation of amino-terminal PTHrP occurs 
in these cells, possibly mediated by PTH1R, or that amino-terminal PTHrP binds to 
intranuclear PTH1R.
Absence of hypercalcaemia in these patients with PTHrP-expressing pancreatic 
adenocarcinomas is similar to the situation seen in patients with prostatic 
adenocarcinoma, but contrasts to breast adenocarcinoma where hypercalcaemia is 
common. Possible explanations for this may be that PTHrP is produced and released 
in insufficient quantities to cause hypercalcaemia, or that PTHrP expressed by these 
tumours is degraded within the pancreas which is rich in enzymes, or alternatively 
that PTHrP is processed into peptides that do not cause hypercalcaemia.
61Although the function of PTHrP in pancreatic cancer is unknown, it is known to 
regulate growth in other tumour types, and Bouvet et al have demonstrated that 
exogenous PTHrP (1-34) stimulates growth in the human pancreatic cell line AsPC-1. 
The finding of the expression of PTHrP and its receptor in exocrine pancreatic 
adenocarcinoma warrants further investigation, particularly if PTHrP is confirmed to 
have growth-regulating effects.
62Chapter 3  EXPRESSION OF PARATHYROID HORMONE- 
RELATED PEPTIDE AND PARATHYROID HORMONE TYPE 1 
RECEPTOR IN NEUROENDOCRINE TUMOURS
3.1  Introduction
Neuroendocrine tumours are a relatively rare family of tumours that occur in tissues 
that contain cells derived from the embryonic crest, neuroectoderm, and 
endoderm.cxhv Thus they may occur at many sites throughout the body, although the 
majority occur within the gastro-entero-pancreatic axis. The histological diagnosis of 
neuroendocrine tumours relies first on the identification of general markers of 
neuroendocrine differentiation, and then on cell-specific characterisation. 
Neuroendocrine differentiation is evaluated by immunohistochemistry using 
antibodies against secretory granule proteins (chromogranin A, synaptophysin) and 
cytosolic proteins (neuron-specific enolase, protein gene product 9.5). The cell- 
specific characterization of neuroendocrine tumours requires hormone 
immunohistochemistry.cxlv
Neuroendocrine tumours are generally considered to comprise of two main tumour 
groups: pancreatic endocrine or islet cell tumours and carcinoid tumours. Pancreatic 
endocrine tumours may be further subclassified and named according to the hormone 
that they secrete, and consequently produce an associated clinical syndrome, for 
example, gastrinoma manifesting with the characteristic Zollinger-Ellison syndrome, 
which is caused by hypergastrinaemia associated with hypersecretion of gastric acid; 
or insulinoma characterised by hypersecretion of insulin and hypoglycaemia. 
Carcinoid tumours are traditionally considered to be serotonin (5 hydroxytrytophan) 
secreting, but frequently produce many other hormone products, including kinins, 
prostaglandins, substance P, gastrin, somatostatin, corticotrophin, and chromogranin
^  cxlvi
63PTHrP-secreting pancreatic endocrine tumours associated with hypercalcaemia are 
becoming increasingly recognised as a potential subgroup of pancreatic endocrine 
tumours.cx,v Pancreatic endocrine tumours not associated with hypercalcaemia have 
also been shown to produce PTHrP. Drucker et al reported a survey of 15 human islet 
cell tumours not associated with HHM, and found that 13 (87%) stained for PTHrP.cvl 
Carcinoid tumours however are infrequently associated with hypercalcaemia, 
although HHM has been reported.cxlvn,cxlvui There are no reports in the literature of 
immunohistochemical expression of PTHrP or PTH1R in carcinoid tumours.
The purpose of these experiments was:  1) to investigate by immunohistochemistry the 
expression of PTHrP and PTH1R in resection specimens from normocalcaemic 
patients with a variety of neuroendocrine tumour types; 2) to investigate PTHrP and 
PTH1R expression in neuroendocrine tumour cell lines using immunohistochemistry 
and western immunoblotting; and 3) to assess whether there is a relationship between 
PTHrP/PTHIR expression and cellular proliferation as assessed by Ki67 expression.
3.2  Material and Methods
3.2.a  Patient Tissue Specimens
Forty-seven  patients  with  well-characterised  neuroendocrine  tumour  who  were 
undergoing  treatment  at  the  Royal  Free  Hospital  were  selected.  Only  the  patients 
whose paraffin-embedded tissues from resection specimens or biopsies were available 
were included in the study. The following clinicopathological details about the tumour 
case were collected:  histological  evidence  of vascular invasion,  local  invasion,  and 
perineural  invasion,  and  the presence  of tumour metastases  to  bone,  liver  or  other 
organs (Table 5).
All of the patients had been normocalcaemic prior to their procedures. All patients 
had given consent for the use of the tissue for research, under ethical approval by the 
Royal Free Hospital ethics committee. Sequential sections (5pm thick) were cut with 
a microtome from the formalin-fixed, paraffin-embedded tissues, mounted on APES- 
coated slides, and dried overnight at 60°C.
64Table 5  Patient population and histological details of neuroendocrine tumour
resection specimens studied.
Case
No.
Sex Age
(years)
Description of 
Resection/Biopsy Specimen
Tumour Invasion Primary Tumour Other metastases
Local
Blood
vessels nerves
Bone Other Organs
1 M 59 lymph node resection yes no no appendiceal carcinoid no liver, LN
2 F 16 duodenum, jejunum yes no yes ileal carcinoid yes liver, lung
3 M 73
biopsy of paraaortic/ adrenal 
mass N/A N/A N/A unknown primary yes
liver, paraaortic 
LN
4 F 74 liver nodule N/A N/A N/A PET yes liver
5 F 31 gastric tumour yes no no ileal carcinoid yes liver
6 F 54 lung tumour yes no no bronchial carcinoid no none
7 F 46
hemicolectomy
specimen yes yes yes appendiceal carcinoid no liver, LN
8 F 47 liver nodule no no no
gastric
paraganglioma no liver
9 F 28 appendiceal tumour yes no no appendiceal carcinoid no none
10 F 31 liver metastasis N/A N/A N/A ampullary PET no liver
11 M 35 biopsy of liver metastasis yes N/A N/A PET yes liver
12 M 74 liver nodule yes yes yes
pancreatoduodenal
PET yes soft tissue
13 M 81 ileal tumour yes no yes ileal carcinoid no LN
14 F 74 neck lymph node yes no no unknown primary no liver, LN
15 F 35 thymic carcinoma yes yes no thymic carcinoma no
liver, lungs, 
local
16 M 56 small bowel tumour yes yes no ileal carcinoid no liver, LN
17 F appendiceal tumour yes no no appendiceal carcinoid no none
18 M 55 pancreatic tumour no no no insulinoma no none
19 M 56 liver nodule yes yes yes ileal carcinoid yes LN, Liver
20 F 46 gastric biopsy N/A N/A N/A gastric carcinoid no liver
21 M 43 bone marrow aspirate N/A N/A N/A PET yes liver, skin
22 F 48 pancreatic tumour yes no no PET no
liver, spleen, 
LN
23 F 70 mesenteric mass no no no unknown primary no LN
24 F 43 pancreatic tumour yes yes no pancreatic carcinoid no liver
25 M 43 appendix yes no no appendiceal carcinoid no none
26 M 80 duodenal biopsy N/A N/A N/A duodenal carcinoid no none
27 M 79 neck lymph node no no no
medullary thyroid 
cancer no LN, local
28 F 59 ileal tumour yes yes yes ileal carcinoid no LN
29 M 65 biopsy of liver metastasis N/A N/A N/A ileal carcinoid no liver
30 M 58 sigmoid colon tumour yes yes no sigmoid carcinoid no none
31 M 42 mesenteric tumour nodule yes no no paraganglioma yes liver, lung, LN
32 M 58 small bowel tumour yes yes no ileal carcinoid no liver, LN
33 M 45 pancreatic tumour yes no no PET no liver
34 F 41 duodenal tumour yes yes no ampullary PET no S.I, liver, LN
35 F 56 pancreatic biospy no yes no insulinoma no none
36 M 33 biopsy of liver metastasis yes no no PET no liver
37 F 49 pancreatic tumour no no no PET no none
38 M 70 gastric biopsy yes N/A N/A gastric carcinoid no none
39 M 44 ileal biopsy N/A N/A N/A ileal carcinoid no Liver
40 F 66 neck tumour no no no paraganglioma yes Liver, LN
41 M 43 biopsy of rectal tumour yes no no rectal carcinoid no liver
42 M 66 biopsy of  brain tumour yes no no unknown primary no unknown
43 M 36 liver biopsy N/A N/A N/A PET no liver, LN
44 F 56
tumour in duodenum/head of 
pancreas yes yes yes PET no liver
45 F 53 liver biopsy yes no no PET no liver
46 M 75 gastric biopsy yes N/A N/A gastric carcinoid no no
47 M 76 small bowel mass resection No yes no colonic carcinoid no LN, local
Legend: F = female, M = male, PET = pancreatic endocrine tumour, LN = lymph node
653.2.b  Cell Lines
The  following  neuroendocrine  cell  lines  were  studied:  BON  (human  endocrine 
pancreatic  tumour),  CRI-G1  (rat  NEDH  islet  cell  tumour),  NCI-H727  (human 
bronchial carcinoid), and RIN 5F (rat islet cell tumour). The BON cell line was a gift 
from Professor CM Townsend (Department of Surgery, University of Texas, USA). 
The  other  cell  lines  were  obtained  from  the  European  Collection  of Animal  Cell 
Cultures. To culture the BON cells, a 1:1 mixture of F12K nutrient mixture (Gibco™, 
Invitrogen  Ltd,  Paisley,  UK)  and  DMEM  (Sigma)  supplemented  with  10%  FCS 
(Sigma) was used.  The CRI-G1  cells were cultured in DMEM containing  10% FCS 
and 2mM  L-glutamine.  The NCI-H727  and RIN  5F  cells were  cultured  in RPMI- 
1640 medium (Sigma) containing 10% FCS and 2mM glutamine. The human prostate 
carcinoma cell line PC3 was used as a positive control. All cells were grown at 37°C 
in a humidified 95% air - 5% CO2 atmosphere.
3.2.c  Immunohistochemistry on Patient Tissue Sections
3.2. c. 1  Anti-PTHrP and Anti-PTHIR
Sequential sections were tested with the same antibodies (anti-PTHrP, anti-PTHIR), 
by  the  same  method  as  described  in  Chapter  2.  Sections  were  examined  by  light 
microscopy and scored by two independent observers using the previously described 
method.
3.2.C.2  Anti-Human Ki-67 Antisen
The Ki-67 antigen is a nuclear protein, which is defined by its reactivity with 
monoclonal antibody from the Ki-67 clone.cxhx It is preferentially expressed in cell 
nuclei during all active phases of the cell cycle (Gj, S, G2 and M-phases), but is 
absent in quiescent or resting cells (Go). Monoclonal mouse anti-human Ki-67 (clone 
MIB-1) (Dako) was optimised on paraffin sections from human tonsil.0 1  Antigenic 
unmasking was carried out by pressure cooking the slides at 115 °C in 0.1M citrate 
buffer, pH 6.0 for 135 seconds. A dilution of 1 in 100 was chosen for subsequent 
experiments. All experiments were performed at room temperature, and were 
validated by the inclusion of negative (prepared by omission of the primary antibody) 
and positive (tonsil) control sections. A standard three-step immunoperoxidase
66technique with diaminobenzidine as a chromogen (ABC) was used for detection of the 
Ki67 antigen (Appendix III).
3.2.c.3  Evaluation of  Ki67 stainim
Tumour nuclei showing distinct immunostaining were counted as positive. The 
percentage of positively staining tumour cell nuclei was estimated from four 
representative x20 magnification fields. For statistical analyses, percentages were 
grouped as being:  1  = <1%, 2 = 1-5%, 3 = 6-10%, 4 = 11-30%, 5 = 31-50%, 6 = 
>50%.
Statistical analyses were performed using the Spearman rank correlation test, and the 
Mann-Whitney U non-parametric test for group differences as previously described in 
Chapter 2.2.e.
3.2.d  Immunohistochemistry on Cultured Cells
Cells were seeded onto four-well slides (Beckton Dickenson, NJ, USA), and grown to 
approximately 80% confluency. Immunohistochemical expression of PTHrP and 
PTH1R was assessed using the APAAP method of detection and Fast Red as a 
chromogen. No pre-treatments were given. After nuclear counterstaining, cells were 
fixed with 10% normal buffered formaldehyde (NBF), air dried and mounted in 
Loctite UV (Loctite, UK) adhesive. Experiments were validated by the inclusion of a 
negative control well (incubated in PBS in replacement of primary antibody), and a 
positive control well (PC3 cells). For the anti-PTHrP antibody, the specificity of 
staining was further validated by the inclusion of a well that was incubated with a 
primary antibody solution of the same concentration of antibody that had been pre­
absorbed overnight with excess immunizing peptide. Sections were examined by light 
microscopy and scored by two independent observers using the method previously 
described (Chapter 2.2.d).
673.2.e  Western Immunoblotting
Lysates of the BON, CRI-G1, NCI-H727, RIN 5F cell lines, and the prostatic 
adenocarcinoma cell line PC3 (chosen as positive control), were prepared by the 
method outlined in Chapter 2.2.f. Lysate volumes corresponding to lOpg of protein 
were loaded onto Laemmli SDS-polyacrylamide gels, run and electrotransferred 
according to the previously described method. Immunoblotting was performed on the 
membranes using the following antibodies: anti-PTHrP (1-10) (Aphton), at a dilution 
of 1  in 200; and anti-PTHrP (1-34), anti-PTHrP (38-64), and anti-PTHIR, at the 
concentrations previously used. For the PTHrP (1-10) and PTHrP (1-34) antibodies, 
additional positive controls of 15pg of immunizing peptide were included in each run 
and the results were further validated by incubating parallel blots with the same 
concentration of antibody that had been pre-absorbed overnight with excess 
immunizing peptide. Bands were considered to represent PTHrP peptides only if they 
were abolished or significantly by pre-absorption.
3.3  Results
3.3.a  Immunohistochemistry on Tissue Sections
3.3.a.l  Expression of  PTHrP and PTH1R
Positive cytoplasmic staining for PTHrP was seen in tumour cells in the majority of 
neuroendocrine resection specimens studied [38 of 47 (80.9%)] (Figure 13). A 
relatively higher number of carcinoid tumours than pancreatic endocrine tumours 
showed positive cytoplasmic staining for PTHrP [22 of 25 (88%) versus 12 of 16 
(75%)] (Table 6). Positive cytoplasmic staining for PTH1R was also seen in the 
majority of the neuroendocrine tumour resection specimens [40 of 47 (85.1%)]
(Figure 13). Again, more carcinoids than pancreatic endocrine tumours stained 
positively [22 of 25 (88%) versus 13 of 16 (81.3%)] (Table 6). Seventy-two percent of 
tumours showed positive staining for both PTHrP and PTH1R. Variable staining for 
PTHrP and PTH1R was seen in normal vascular endothelial cells, neurons, some 
normal epithelial cells, and in adjacent normal pancreatic islets. Preabsorption of the
68antibody with the immunizing peptide abolished all staining for PTHrP. Staining for 
PTH1R was abolished by substitution of normal mouse serum for primary antibody. 
There was a significant positive correlation between the intensity of tumour staining 
for PTHrP and PTH1R (r = 0.323 p = 0.027) across all of the groups. There was no 
significant difference in the intensity of staining for either antigen in specimens from 
primary (n = 26) or secondary tumour (n = 21) specimens. There was no significant 
association between the presence or intensity of staining for either PTHrP or PTH1R 
and the other clinicopathological characteristics of the tumours (i.e. histological 
evidence of vascular invasion, local invasion, and neural invasion, and the presence of 
tumour metastases to bone, liver or other organs).
Table 6  Median tumour cell cytoplasmic immunoreactive product for PTHrP 
and PTH1R in the neuroendocrine tumour resection specimens and biopsies studied.
Type of Tumour No of 
Samples
PTHrP
positive
Median
score
(0-9)
(range)
PTH1R
positive
Median
score
(0-9)
(range)
Both
PTHrP
and
PTH1R
positive
Carcinoid 25 22 (88%) 4 (0-6) 22 (88%) 3 (0-9) 20 (80%)
Pancreatic 
endocrine tumour
16 12 (75%) 4 (0-6) 13
(81.3%)
3 (0-6) 11
(68.8%)
Other 6 4 (66.7%) 2 (0-4) 5 (83.3%) 3 (0-6) 3 (50%)
Legend: The intensity of staining was graded on a scale from 0 to 3 where, 0 
indicated no staining; 1 indicated weak intensity of staining; 2, moderately intense 
staining; and 3, most intense staining. Sections were also given a score to grade the 
extent of staining, such that less that 25% positive cells = 1; 25-75% cells = 2; and 
more than 75% = 3. To obtain a numerical score, the intensity of staining was 
multiplied by the number of cells stained.
69Figure 13  Immunohistochemistry showing positive tumour cell staining for 
PTHrP (figures a, c, e, & g) and PTH1R (figures b, d, f, & h) in resection specimens 
of neuroendocrine tumours. Positive staining appears as a red precipitate. Variable 
staining for both peptide and receptor was seen in normal vascular endothelial cells, 
neurons, some normal intestinal epithelial cells, and in pancreatic islets.
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There was a significant difference in Ki67 staining in primary and secondary tumours 
( p = 0.034), the Ki67 score being higher in secondary tumours (median percentage 
cells positive 5-10%) compared to primary tumours (median percentage cells positive 
1-5%). Statistical analysis showed a significant negative correlation between the 
expression of PTHrP and the Ki67 score (r = -0.378, p = 0.016).
713.3.b  Immunohistochemistry on Cells
There was variable positive cytoplasmic staining for PTHrP and PTH1R in all 4 cell 
lines tested (Table 7). There was also nuclear staining for PTHrP in the CRI-G1 cell 
line in approximately 15% of the cells (Figure 14). Staining for PTHrP and PTH1R 
was abolished by preabsorption of the PTHrP antibody with immunizing peptide, and 
by substitution of normal mouse serum for PTH1R antibody, respectively.
Table 7  Immunohisto chemical expression and  localisation of PTHrP and
PTH1R in the neuroendocrine cell lines studied.
Cell line Intensity and location of 
immunostaining for 
PTHrP
Intensity and location of 
immunostaining for 
PTH1R
BON 9(C) 6(C)
CRI-G1 9 (C & N) 6(C)
NCI-H727 3(C) 6(C)
RIN 5F 6(C) 3(C)
Legend: C = cytoplasmic, N = nuclear, scoring as described in table 6.
72Figure  14  Immunohistochemistry showing positive staining for both  PTHrPand PTH1R 
in rat islet cell tumour cell line CRI G 1.
Figure (a) shows cytoplasmic and nuclear staining for PTHrP on cultured CRI G 1   cells. 
The arrows point to positive nuclear staining. (Original magnification xlOO)
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Figure (b) shows cytoplasmic staining for PTFUR on cultured CRI Gl  cells  (Original 
magnification xlOO).3.3.C  Western Immunoblotting
PTHrP (1-10)
Bands that were almost completely abolished by preabsorption were seen at 30, 35 
and 44 kDa in all cell line lysates. An additional band at 15 kDa was observed in the 
BON, CRI-G1, and NCI-H727 cell lysates (figure 15a), and in the control cell line 
PC3.
PTHrP (1-34)
A distinct band that was completely abolished by preabsorption was present for 
PTHrP (1-34) at approximately 5 kDa. A single band at 35 kDa that was abolished by 
pre-absorption was present in all cell line lysates. An additional band at 17 kDa was 
seen in BON, CRI-G1, and PC3 lysates, and at 30 kDa in the RIN 5F lysate.
PTHrP (38-64)
A single band at 35 kDa was observed in lysates from the four neuroendocrine cell 
lines. A 15 kDa band was observed in RIN 5F and in PC3 cell lysates.
PTH1R
The PTH1R antibody reacted with protein bands at approximately 60, 80 and 160 kDa 
in all cell lines tested. There was an additional band at 45 kDa in the PC3 lysate 
(figure 15b).
74Figure  15  Western  immunoblots  for  PTHrP  (1-10)  and  PTH1R  on  whole  cell 
lysates from neuroendocrine tumour cell lines
Figure (a) is a representative immunoblot for PTHrP (1-10)  Bands that are attenuated 
by  pre-absorption  are  seen  at  30  kDa,  35  kDa,  and  44  kDa  in  all  cell  lysates.  An 
additional  band  at  15  kDa  was  observed  in  the  BON,  CRI-G1,  and  NCI-H727  cell 
lysates
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Figure (b) is a representative immunoblot for PTH1R  Distinct bands are seen at 60 
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753.4  Conclusions
This immunohistochemical study shows that PTHrP and PTH1R protein are highly 
expressed in both primary and metastatic neuroendocrine tumours, and in 
neuroendocrine tumour cell lines. PTHrP and PTH1R expression in neuroendocrine 
tumour cell lines was confirmed on western immunoblotting from whole cell lysates. 
The bands obtained for PTHrP are similar to those obtained using the same antibodies 
in pancreatic adenocarcinoma cell line lysates, and are appropriate sizes for PTHrP 
(1-139) and PTHrP (1-141) molecules and polymerised PTHrP molecules, or possible 
glycoylated forms of mature PTHrP. Again, smaller bands of sizes, more appropriate 
for amino-terminal and mid-fragment daughter species, were not detected. The bands 
obtained for the PTH1R are also appropriate sizes for the non-glycosylated PTH1R, 
the glycosylated receptor,cxhn dimers of the glycosylated receptor, and a truncated 
form of the receptor.cxh
Although generally slow growing, neuroendocrine tumours are often widely 
metastasised at presentation, and a significant proportion demonstrates aggressive 
behaviour that may be difficult to manage. Surgery has a potentially curative role in 
resectable disease and has a role in debulking liver metastases by liver resection. The 
role of systemic chemotherapy is generally limited to well-differentiated pancreatic 
endocrine tumours, and alpha interferon is of limited benefit in patients with large 
volume disease. Somatostatin analogues, while useful for the control of hormone- 
mediated symptoms, have little in the way of anti-tumour effect. Treatment of liver 
metastases with loco-regional ablative strategies, such as hepatic-artery embolization 
and trans-arterial chemoembolization, provide an effective alternative treatment for 
some hepatic metastases, however these procedures have no impact on extra hepatic 
disease and carry a significant (up to 6%) mortality rate.
Promising new therapies include receptor-targeted radionuclide therapy, taking 
advantage of the common expression of somatostatin receptor in neuroendocrine 
tumours. The concept of this form of targeted therapy is to visualise the tumour with 
the diagnostic tracer (Indium-111-octreotide) in order to make an estimation of 
tumour load, and then change the isotope label on the peptide to a higher energy 
isotope, preferably a p-emitter, in order to target radiotherapy to the tumour cell
76(‘magic bullet’). Recent trials using a number of different labelled somatostatin 
analogues in patients with therapy resistant and progressive disease have shown 
promising results.0 1 1 ’cln’cl,n
Two problems may occur with somatostatin receptor-targeted therapy, namely that 
these patients are frequently on concurrent treatment with somatostatin analogues, 
such as octreotide, in order to control hormonal symptoms, and therefore a proportion 
of somatostatin receptors may down-regulated or occupied, and unavailable for 
cellular binding and uptake of a radiolabeled somatostatin analogue. Another problem 
is that neuroendocrine tumours may ‘de-differentiate’ and lose the ability to produce a 
variety of peptides, such as chromogranin A, as well as G-protein-coupled receptors, 
such as somatostatin receptors. This usually coincides with the development of 
aggressive widely disseminated disease which is resistant to current existing 
treatments, in particular somatostatin receptor-targeted therapy which is ineffective in 
this situation. PTH1R is commonly expressed by these tumours. If PTH1R expression 
is not lost as these tumours ‘de-differentiate’, PTHlR-targeted therapies may be a 
promising new alternative treatment strategy for these difficult to treat tumours. 
Furthermore, PTH1R has been previously localised to the nucleus,ln1’cllv as receptor 
ligands, which may make this receptor a useful portal of entry to the tumour cell 
nucleus.
The observation that there is a negative correlation between immunoreactivity for 
PTHrP and the proliferation marker Ki67 can be interpreted in two ways:  1) that 
PTHrP expressed by neuroendocrine tumour cells inhibits its own growth, and/or 2) 
that PTHrP expression by neuroendocrine tumour cells is diminished as the tumour 
cell escapes cell cycle regulatory mechanisms and increases in proliferation. There 
was no correlation between PTH1R immunoreactivity and Ki67 staining, which was 
also not significantly different in primary and secondary tumours. If PTH1R 
expression is not lost as these tumours increase in proliferation and metastasise, 
PTH1R may further be an attractive target for receptor-targeted therapy.
The co-expression of PTHrP and PTH1R protein in human neuroendocrine tumours, 
and the positive correlation between the intensity of staining for PTHrP and PTH1R, 
suggests that an autocrine and/or paracrine loop exists for PTHrP in these tumours.
77The detection of PTHrP in the nucleus of the rat islet tumour cell line CRI G1, also 
suggests that nuclear translocation of PTHrP may occur in these cells.
78Chapter 4  EXPRESSION OF PARATHYROID HORMONE- 
RELATED PEPTIDE AND THE PARATHYROID HORMONE 
TYPE 1 RECEPTOR IN HEPATOCELLULAR CARCINOMA
4.1  Introduction
The expression of PTHrP and PTH1R by the well differentiated hepatocellular 
carcinoma cell line HepG2 was described by Li et al in 1996.clv However there are 
few published data relating to the expression of PTHrP in human hepatocellular 
carcinoma specimens, and to date, none on the expression of PTH1R. This is perhaps 
surprising, as elevated serum PTHrP causing hypercalcaemia associated with 
hepatocellular carcinoma has been described,clv1’clvn and an association of 
hypercalcaemia with hepatocellular carcinoma has been known about since Keller 
first described it in 1965.clv,n
In contrast, immunoreactivity for PTHrP has been documented by Roskams et al and 
others in human cholangiocarcinoma resection specimens,cllx’clx and in human liver 
cell cultures with a bile duct phenotype.clxl Cholangiocarcinoma is well known to be 
associated with humoral hypercalcaemia of malignancy,0 1 ™’clxm’clxiv and indeed the 
first case of malignancy-associated hypercalcaemia was reported in 1923 by Zondek 
et al in a patient with cholangiocarcinoma.0 1 1
The aims of these experiments were:  1) to investigate by immunohistochemistry the 
expression  of PTHrP  and  its  corresponding  PTH1R  in  hepatocellular  carcinoma 
tumour resection specimens from patients who were normocalcaemic  at the time of 
resection;  and  2)  to  investigate  by  immunohistochemistry  and  western 
immunoblotting the expression of PTHrP and PTH1R in hepatocellular cancer lines.
794.2  Materials and Methods
4.2.a  Patient Tissue Specimens and Cell Lines
4.2. a. 1  Patient Tissue Specimens
Twenty  cases  of well-characterised  hepatocellular  carcinoma  (HCC)  were  selected 
from the pathology archives of the Royal Free Hospital from May 1997 to December 
2000.  The study population was comprised of 20 patients in total, 4  female and  16 
male,  median  age  54  years  (range  36-69  years).  Sixteen  of the  cases  were  from 
patients  who  had  undergone  orthotopic  liver  transplantation  at  the  Royal  Free 
Hospital for cirrhosis, and 4 were from patients who had undergone segmental hepatic 
resection  for HCC  (case numbers  10,  18,  19,  20)  (Table  8).  All patients had been 
normocalcaemic pre-operatively, and all had given consent for the use of their liver 
tissue for research according to a protocol approved by the Royal Free Hospital ethics 
committee. Liver specimens had been received within one hour after removal, sliced 
and  fixed  in  formalin  for 24  hours.  Protocol  samples  were  paraffin processed  and 
tissue sections (H & E and reticulin stains) were prepared using routine histological 
laboratory  standard  procedures.  Sequential  sections  (5 pm  thick)  were  cut  with  a 
microtome  from the  formalin-fixed,  paraffin-embedded tissues,  mounted on APES- 
coated slides, and dried overnight at 60°C.
The  following  clinicopathological  details  about  the  tumour  case  were  collected: 
tumour  size,  tumour  differentiation,  histological  evidence  of  vascular  and  local 
invasion, and the presence of multiple hepatocellular tumours.
4.2. a. 2  Cell Lines
The following tumour cell lines were  studied:  PLC/PRF/5  (human liver hepatoma), 
HepG2  (human hepatocyte carcinoma)  and MCA RH  7777  (rat buffalo hepatoma). 
The cell lines were obtained from the European Collection of Animal Cell Cultures. 
PLC/PRF/5  and HepG2  were  grown in DMEM  containing  10%  FCS  and 2mM  L- 
glutamine.  MCA  RH  7777  was  grown  in  DMEM  containing  10%  FCS,  4mM  L- 
glutamine,  1% non-essential amino acids (NEAA) (Life Technologies, Paisley, UK), 
and  1% vitamins (Life  Technologies).  The human prostate carcinoma cell  line PC3
80was used as a positive control. All cells were grown at 37°C in a humidified 95% air - 
5% CO2 atmosphere.
4.2.b  Immunohistochemistry
4.2. b. 1  Patient Tissue Sections
Sections were deparaffinized in xylene,  and rehydrated through graded alcohol  and 
distilled water.  The  sections were tested with anti-PTHrP  (1-10)  antibody (Aphton) 
and anti-PTHIR (Lab  Vision)  at the  same  concentrations  as  outlined in Chapter 2. 
The  same  methods  were  employed,  with  the  exception  that  endogenous  avidin- 
binding activity was blocked by incubating the tissue sections with 0.1% avidin for 15 
minutes  and  then  after rinsing,  incubating  them  with  0.01%  biotin  for  15  minutes 
(Vector Laboratories  Ltd,  Peterborough, UK).  This  additional  stage was performed 
after  any  pre-treatment,  and  before  incubation  with  rabbit  serum.  Sections  were 
examined by light microscopy  and  scored by two  independent observers  using  the 
method  described  in  Chapter  2.2.d.  Statistical  analyses  were  performed  by  the 
previously described methods (Chapter 2.2.e).
4.2.b.2  Cultured Cells
Immunohistochemical detection of PTHrP and PTH1R was carried out on cultured 
cells according to the previously described method (Chapter 3.2.d). Experiments were 
validated by the inclusion of a negative control well (incubated in PBS in replacement 
of primary antibody), and a positive control well (PC3 cells). As a competitive 
control, in another well, cells were incubated with primary anti-PTHrP antibody that 
had been pre-incubated overnight at 4°C with 0.25mg of immunizing peptide.
Sections were examined by light microscopy and scored by two independent 
observers using the method previously described in Chapter 2.2.d.
814.2.C  Western Immunoblotting
Lysates of the following cell lines were prepared by the method outlined in Chapter
2.2.f: PLC/PRF/5, HepG2 and PC3. Volumes of lysate corresponding to lOpg of 
protein were loaded onto Laemmli SDS-polyacrylamide gels, run and 
electrotransferred according to the previously described method. Immunoblotting was 
performed on the membranes using the following antibodies: anti-PTHrP (1-10), anti- 
PTHrP (1-34), anti-PTHrP (38-64), and anti-PTHIR, at the same concentrations as 
previously used. For the anti-PTHrP (1-10) and anti-PTHrP (1-34) antibodies, an 
additional positive control of 15pg of immunizing peptide was included in each run, 
and results were validated by incubating parallel blots with the same concentration of 
antibody that had been pre-absorbed overnight with excess immunizing peptide.
Bands were considered to represent PTHrP peptides only if they were abolished or 
significantly attenuated by pre-absorption.
4.3  Results
4.3.a  Immunohistochemistry
4.3. a. 1  Patient Tissue Sections
All 20 cases of HCC showed positive cytoplasmic tumour cell staining for PTHrP 
[median score 6 (range 3-6)] (Table 8; Figure 16) and positive cytoplasmic tumour 
cell staining for PTH1R [median score 4 (range 1-6)] (Table 8; Figure 17). In the 
majority of the specimens studied there was also generalised weaker staining for 
PTHrP and PTH1R in the surrounding liver tissue [median scores, 4 (range 0-6) and 3 
(range 0-6) respectively]. In normal bile ducts there was strong staining for PTHrP 
[median score 9 (range 3-9)] and variable staining for PTH1R [median score (range 0- 
4)]. Pre-absorption of the antibody with the immunizing peptide abolished all staining 
for PTHrP. All staining for PTH1R was abolished by substitution of normal mouse 
serum for primary antibody.
82Table 8  Histological details and immunohistological expression of
PTHrP and PTH1R in resection specimens from 20 patients with hepatocellular 
carcinoma.
Case
No
Age
(yrs)
Sex Tumour
different­
iation
Tumour
size
(mm)
Tumour invasion Multiple
HCC
tumours
Aetiology of 
Liver 
Disease
Tumour cell 
staining
Vascular Local PTHrP
(0-9)
PTH1R
(0-9)
1 48 F moderate 20 no no no ALD/AATD 6 4
2 61 M moderate 22 no no no cryptogenic 6 4
3 58 M moderate 75 yes yes satellite cryptogenic 6 6
4 54 M well 12 no yes no HBV/HCV 6 3
5 66 M moderate 59 yes yes yes AATD 6 3
6 61 M well 110 no no yes
non­
cirrhotic 6 3
7 36 M moderate 15 no no yes HBV 6 4
8 42 M moderate 15 no no yes HBV/HDV 6 6
9 52 M well 28 no no no HCV 6 4
10 69 M well 75 no no no HCV 4 1
11 54 M well 9 no no yes ALD 6 6
12 50 M well 45 yes yes no ALD 6 4
13 52 M moderate 29 no no yes
HBV/
HCV 6 4
14 46 M well 45 no no yes ALD 3 1
15 58 M well 33 no no yes HBV 6 4
16 51 F moderate 70 no no yes HCV 6 3
17 57 M well 12 no yes no viral 6 3
18 55 M moderate 15 no no no
HBV/non-
cirrhotic 6 6
19 66 F moderate 55 no no no
non­
cirrhotic 6 4
20 68 F moderate 195 no no no
non­
cirrhotic 4 4
Legend: M = male, F = female, HBV = Hepatitis B virus, HCV = Hepatitis C vims, 
HDV  =  Hepatitis  D  vims,  ALD  =  Alcoholic  liver  disease,  AATD  =  alpha-1  
antitrypsin deficiency
The  immunoreactive  product  was  scored  between  0  and  9.  To  obtain  a  numerical 
score, the intensity of staining (scored from 0 to 3) was multiplied by the number of 
cells stained (scored between 0 and 3).
83There was no significant difference between the tumour cell staining scores for 
PTHrP or PTH1R and the grade of tumour differentiation (only moderate or well 
differentiated tumours were included in this series), tumour size (grouped for 
statistical evaluation into tumours that were < 20mm or > 20mm), histological 
evidence of vascular invasion, local invasion, and the presence of multiple 
hepatocellular carcinoma tumours. There was a positive correlation between the 
tumour cell staining obtained for PTHrP and PTH1R that approached significance (R 
= 4.4,/? = 0.054).
84Figure  16  Immunohistochemistry  showing  positive  tumour  cell  staining  for
PTHrP in resection specimens of human hepatocellular carcinoma
The  figures  are  images  from  three  different  cases  of  hepatocellular  carcinoma. 
Positive staining appears as a red precipitate
Figure  (a) shows  strong positive cytoplasmic  staining for  PTHrP in tumour cells and 
in  normal  hepatic  ducts,  with  weaker positive cytoplasmic  staining in  hepatocytes  in 
the  surrounding  cirrhotic  tissue.  Figure  (b)  shows  positive  cytoplasmic  staining  for 
PTHrP  in  a  subset  of neoplastic  cells  within  the  tumour  Figure  (c)  shows  positive 
tumour  cell  staining  for  PTHrP  with  strong  staining  in  some  tumour  cells.  (The 
images are photographed at x 100 magnification)
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Figure  17  Immunohistochemistry  showing  positive  tumour  cell  staining  for
PTH1R in resection specimens of human hepatocellular carcinoma.
Positive  staining  appears  as  a  red  precipitate.  Figures  (a)  and  (b)  are  images  of the 
same two cases of hepatocellular carcinoma as shown in Figure  16 (a) and (b)
Figure  (a)  shows  strong  cytoplasmic  staining for  PTH1R  in  some  tumour cells,  and 
weak  cytoplasmic  staining  in  the  surrounding  cirrhotic  tissue  (photographed  at 
magnification xlOO).  Figure (b) shows positive cytoplasmic  staining for PTH1R  in a 
subset  of neoplastic  cells  within  the  tumour  (photographed  at  magnification  xlOO). 
Figure (c) is a detail of the case in figure (a) (photographed at magnification x 200).
87F ip ure  1
Figure 17(h)4.3.  a. 2  Cultured Cells
There was variable positive cytoplasmic staining for PTHrP and PTH1R in all 3 cell 
lines tested (Table 9; Figure  18).  There was also nuclear staining for PTHrP  in the 
MCA RH 7777 cell line in 1-5 % of the cells.
Table 9  Immunohistochemical localisation of  PTHrP and PTH1R in the
hepatocellular carcinoma cell lines studied.
Cell line Intensity of staining and localisation of
PTHrP (0-9) PTH1R (0-9)
HepG2 3  (C) 3  (C)
MCA RH 7777 3  (C&N) 6  (C)
PLC/PRF/5 2  (C) 4  (C)
Legend: C = cytoplasmic, N = nuclear
Figure 18  Immunohistochemistry showing positive staining for both PTHrP and 
PTH1R in rat hepatocellular carcinoma cell line MCA RH 7777.
Figure 18a shows cytoplasmic and nuclear staining for PTHrP in cultured MCA RH 
7777 cells. The arrows point to positive nuclear staining. (Original magnification 
xlOO).
891   inure  18  b
Figure  18b  Immunohistochemistry  showing  positive  cytoplasmic  staining  for 
PTH1R  in  rat  hepatocellular  carcinoma  cell  line  MCA  RH7777  (original 
magnification x200).
904.3.b  Western Immunoblotting
PTHrP (1-10)
Bands that were almost completely abolished by preabsorption were seen at 15, 30, 35 
and 44 kDa in all 3 cell line lysates (figure 19a).
PTHrP (1-34)
A distinct band that was completely abolished by preabsorption was present for 
PTHrP (1-34) at approximately 5kDa. Distinct bands that were completely abolished 
by preabsorption were seen at 17, 35, and 45 kDa in all 3 cell line lysates.
PTHrP (38-64)
Bands at 15, 35, and 50 kDa were observed in HepG2 and PLC/PRF/5 lysates, and at 
15- and 50 kDa in the control PC3 lysate.
PTH1R
The PTH1R antibody reacted with protein bands at approximately 60, 80 and 160 kDa 
in all the cell lines tested. There was an additional band at 45 kDa in the PC3 lysate 
figure 19b.
91Figure 19  Western immunoblots for PTHrP (1-10) and PTH1R on whole cell 
lysates from hepatocellular carcinoma cell lines.
Figure (a) is a representative immunoblot for PTHrP (1-10). Bands that are attenuated 
by pre-absorption are seen at 17 kDa, 30 kDa, 35 kDa, and 44 kDa in all cell lysates.
HepG2  PLC/PRF/5  PC3
Figure (b) is a representative immunoblot for PTH1R. Distinct bands are seen at 60 
kDa, 80 kDa and 160 kDa in all cell lysates.
HepG2  PLC/PRF/5
924.4  Conclusions
These results show that PTHrP and PTH1R protein are strongly expressed in the 
cytoplasm of tumour cells in human HCC resection specimens and by HCC cell lines. 
PTHrP and PTH1R expression in cell lines was confirmed on western 
immunoblotting from whole cell lysates. Bands obtained for PTHrP and PTH1R were 
comparable to those previously obtained using these antibodies on cell lysates from 
pancreatic cancer and neuroendocrine tumour cell lines. The bands obtained for 
PTHrP are appropriate sizes for PTHrP (1-139) and PTHrP (1-141) molecules and 
polymerised PTHrP molecules, or possible glycosylated forms of mature PTHrP. The 
bands obtained for PTH1R are also appropriate sizes for the glycosylated receptor, 
dimers of the glycosylated receptor, and a truncated form of the receptor. The 60 kDa 
protein band detected by the anti-PTHIR antibody may represent the non­
glycosylated form of the PTH1R which is fully functional and has an estimated 
molecular weight of 60 kDa.clxv>  cxli’cxliii
Hepatocellular carcinoma ranks fifth in frequency among world-wide malignancies, 
and is on the increase in many countries, particularly in areas where hepatitis C virus 
is more common than hepatitis B virus infection.0 1 ™’clxvn’clxvin Indeed, mortality from 
all causes of primary liver cell cancer has almost doubled in 15 years in the UK. The 
prognosis of this cancer remains dismal, with an overall 5-year survival rate world­
wide of only 2% because of late diagnosis.clx,x Alpha-fetoprotein (AFP) is currently 
the most important tumour marker for the diagnosis of HCC. However, as a serum 
tumour marker, AFP lacks sensitivity, as a considerable proportion of HCCs do not 
produce AFP, or elevate AFP serum level only minimally. Thirty-five percent of 
HCCs smaller than 3cm do not produce an elevated AFP levelclxix which makes early 
diagnosis difficult with this marker alone. AFP is also elevated, sometimes to 
equivocally high levels (20-400 ng/ml), in serum from cirrhotic patients in whom the 
majority of HCCs occur. If serum levels of PTHrP, which are undetectable in normal 
individuals, are found to be elevated in patients with HCC, PTHrP may be a useful 
tumour marker for HCC, particularly as it would be released by tumours directly into 
the systemic, rather than the portal circulation.
93A study measuring serum levels of PTHrP in patients with HCC is therefore 
warranted. Assays used for PTHrP detection in serum would have to be sufficiently 
sensitive to detect low levels of circulating PTHrP, as it seems likely that if detected, 
the levels would not be as high as those observed in patients with hypercalcaemia of 
malignancy, as most patients with HCC do not have hypercalcaemia. Additionally, 
any study measuring serum levels of PTHrP in patients with HCC would have to 
incorporate cirrhotic individuals with no evidence of HCC, as PTHrP was found to be 
expressed in background cirrhotic liver, and so may also be detectable in the serum of 
cirrhotic patients.
Both PTHrP and PTH1R were strongly expressed by human HCC tumour cells. The 
intensity of staining for both PTHrP and PTH1R positively correlated, suggesting that 
an autocrine and/or paracrine loop may exist for PTHrP/PTHIR in these tumours. The 
detection of PTHrP in the nucleus of rat buffalo hepatoma cells (MCA RH 7777), 
implies that nuclear transport of PTHrP may also occur in these cells. A possible 
paracrine or autocrine action of PTHrP in hepatoma cells has previously been 
suggested by Li et al who demonstrated that Hep G2 cells could synthesize and 
secrete both immunoreactive and biologically active PTHrP, and express messenger 
RNA for PTHlR.clv They reported that neutralization of endogenous PTHrP secreted 
by these cells, by the addition to the cell media of antiserum to PTHrP, resulted in 
increased cell growth, implying that that PTHrP had growth regulatory effects in these 
cells, in this case inhibitory properties.
The possibility of an autocrine/paracrine pathway for PTHrP/PTHrP, and any possible 
growth regulatory effects in HCC cells warrants further investigation. Despite 
advances in surgical and non-surgical treatments for HCC, the prognosis remains 
extremely poor. If the PTHrP/PTHIR system is found to have a pathophysiological 
role in HCC tumour growth, agents that target this system may be developed, which 
may have a therapeutic role in the management of these tumours.
94Chapter 5  EXPRESSION OF PARTHYROID HORMONE- 
RELATED PEPTIDE AND THE PARATHYROID HORMONE 
TYPE 1 RECEPTOR IN NORMAL LIVER, CIRRHOTIC LIVER, 
PUTATIVE HEPATOCELLULAR CARCINOMA PRECURSOR 
NODULES, AND HEPATOCELLULAR CARCINOMA
5.1  Introduction
The  liver  has  been  reported  in  several  immunohistochemical  studies  to  produce 
PTHrP.  Most  studies  have  observed  immunoreactivity  for  PTHrP  or  detectable 
mRNA  for  PTHrP  in  the  foetal  human  or  rat  liver,  but  only  minimal  or  absent 
expression  in  the  adult  liver.clxx' clxxi’ clxxiil clxxiii'  x  In  a  study  by  Kramer  et  al,cviii 
immunostaining  for  PTHrP  was  observed  in  the  adult  human  liver,  but  was  most 
prominent in blood vessels. Funk et al observed a low level of expression of PTHrP 
mRNA and protein in the  adult rat liver,  which  increased markedly in response to 
inflammatory stimuli (endotoxaemia), where it was found to activate the hepatic acute 
phase response.clxxiv
In  contrast,  in  the  adult  rat,  the  liver  has  been  identified  as  a  site  of  PTH1R 
expression, with relative abundant expression of receptor RNA levels. clxxv’clxxv1’1 1 1 1  A 
large body of literature exists, predating the discovery of PTHrP, describing possible 
hepatic effects of PTH in the liver of the adult rat and dog,  cixxviii,cixxix,cixxx,cixxxi,
clxxxii,clxxxiii, clxxxiv,clxxxv jm p ly in g  p X H l R  e x p re s sio n .
The majority of patients who develop HCC have underlying cirrhosis, which suggests 
that cirrhosis itself represents a preneoplastic condition. Arakawa et al first reported in 
1986  that  an  early  HCC  evolved  in  an  adenomatous  hyperplastic  nodule.clxxxvi 
Subsequently a large number of studies of surgically resected livers were performed 
in Japan and in the West, and the general consensus reached amongst pathologists was
95that  histological  changes  preceding  malignant  transformation  usually  occur  within 
dysplastic  nodules,  i.e.  the  emergence  of hepatocellular  carcinoma  is  a  stepwise 
process.  These  histological  changes  include  an  increase  in  cellularity,  fatty  and/or 
clear  cell  changes,  an  irregular  thin-trabecular  pattern  with  frequent  acinus  and 
pseudogland formations,  cell invasion within the fibrous stroma and vessel walls in 
cirrhotic  livers,clxix  and  a  stepwise  increase  in  abnormal  arterial  luminal  areas 
(intratumoral arterioles) clxxxvil> clxxxvin  Between 40 and 50% of dysplastic nodules are 
believed  to  undergo  malignant  transformation,clxxxix,cxc  and  therefore  many 
pathologists  are  beginning  to  regard  dysplastic  nodules  as  malignant.cxcl  The  early 
HCC is usually well differentiated, and within it evolves less well differentiated HCC.
The observation that PTHrP is expressed in foetal liver,  expressed at a low level or 
not at all in adult liver, and then ‘switched on’  in hepatocellular carcinoma suggests 
that in liver, as in a number of other tissues, PTHrP may play a role as a regulatory 
factor for hepatocyte  growth  and differentiation.  The purpose  of these  experiments 
were:  1)  to  investigate  by  immunohistochemistry the  expression  of PTHrP  and  its 
corresponding  PTH1R  in  human  resection  specimens  from  normal  liver,  cirrhotic 
liver  (regenerating  nodules),  macroregenerative  nodules,  dysplastic  nodules  and 
hepatocellular carcinomas; 2) to evaluate proliferative activity in the tissues (assessed 
by Ki-67 antigen expression); and 3) to assess whether there is a relationship between 
PTHrP/PTHIR expression and proliferative activity.
965.2  Materials and Methods
5.2.a  Patient Tissue Specimens
Thirty-two  cases  of  surgically  resected  livers  were  selected  from  the  pathology 
archives of the Royal Free Hospital from May  1997 to November 2002  (Table  10). 
These  cases  included  13  macroregenerative  nodules  (MRN),  13  dysplastic  nodules 
(DN)  and  20  hepatocellular  carcinomas  (HCC).  Non-neoplastic  livers  displayed 
regenerative nodules in 7 cases, and normal liver in  10 cases. Twenty-two of the 32 
patients  had been transplanted  for cirrhosis  of the  liver.  The  cases  of normal  liver 
were  from  9  patients  who  had  undergone  liver  resection  for  colorectal  metastatic 
adenocarcinoma, one case was from a transplant donor which had not been used for 
technical reasons.  Macroregenerative nodules, dysplastic nodules and hepatocellular 
carcinomas were classified on the basis of morphological characteristics as previously 
described. All of the patients had been normocalcaemic pre-operatively. All patients 
had given consent for the use of liver tissue for research and under ethical approval by 
the  Royal  Free  Hospital  ethical  committee.  All  of the  liver  specimens  had  been 
received within one hour after removal,  sliced  and  fixed  in  formalin  for 24 hours. 
Protocol  samples were paraffin processed  and tissue  sections  (H  &  E  and reticulin 
stains)  were  prepared  using  routine  histological  laboratory  standard  procedures. 
Sequential sections (5pm thick) were cut with a microtome from the formalin-fixed, 
paraffin-embedded tissues,  mounted on APES-coated  slides,  and dried  overnight  at 
60°C.
97Table 10  Patient population, histological details, and aetiology of liver disease
in the surgical resection specimens studied.
Case
Number
Age (years) Sex Aetiology of 
Liver 
Disease
Type of Tissue
1 46 F CRC Normal liver
2 64 M CRC Normal liver
3 64 F CRC Normal liver
4 64 F CRC Normal liver
5 68 M CRC Normal liver
6 50 M CRC Normal liver
7 72 M CRC Normal liver
8 65 F CRC Normal liver
9 55 F CRC Normal liver
10 19 M CRC Normal liver
11 64 M HCV RN
12 63 M ALD RN, HCC
13 39 M HCV RN, MRN, DN
14 56 M ALD RN, DN(x2), HCC(x2)
15 48 M HBV/ALD RN
16 42 M HBV/HDV RN
17 58 M ALD RN
18 54 M HBV MRN(x5)
19 41 M
HCV,
AATD
MRN (x2), DN (x4), 
HCC (x4)
20 60 M HCV MRN
21 55 M HBV, HCV MRN
22 58 M HBV MRN, DN, HCC
23 68 M ALD MRN, HCC (x2)
24 54 M ALD MRN, DN
25 61 M ALD,HCV DN (x3), HCC (x3)
26 46 M HCV DN
27 45 F WD HCC
28 62 M HBV HCC (x2)
29 61 M ALD HCC
30 53 M HCV HCC
31 53 M HCV HCC
32 60 M HBV HCC
Legend: F = female, M = male, CRC = colorectal metastatic adenocarcinoma, HBV = 
Hepatitis B vims, HCV = Hepatitis C vims, HDV = Hepatitis D vims, ALD = 
Alcoholic liver disease, AATD = alpha-1  antitrypsin deficiency, WD = Wilson’s 
disease, RN = regenerative nodule, MRN = macroregenerative nodule, DN = 
dysplastic nodule, HCC = hepatocellular carcinoma.
985.2.b  Immunohistochemistry
Sequential sections were tested with anti-PTHrP (1-10) (Aphton), anti-PTHIR (Lab 
Vision), and anti-Ki67 (DAKO) antibodies, at the same concentrations, and using the 
same methods and as outlined previously. After pretreatments, endogenous avidin- 
binding activity was blocked with an avidin-biotin block as described previously 
(Chapter 4.2.b.l). All experiments were performed at room temperature, and were 
validated by the inclusion of positive control sections. Negative control sections were 
made by substitution of the primary antibody with normal mouse serum; for the anti- 
PTHrP antibody, specificity of staining was further validated by the inclusion of a 
parallel section of tissue that was incubated with a primary antibody solution antibody 
pre-absorbed with immunizing peptide.
Evaluation of PTHrP/PTHIR staining
Sections were examined by light microscopy and scored by two independent 
observers using the previously described method (chapter 2.2.d, chapter 4.2.b.2).
Evaluation of Ki67 staining
A Zeiss Axioscope 2 microscope and an axiocam with axiocam software Axiovision 
3.0 was used to photograph four 20x magnification fields from each lesion. 
Photographs were printed on A4 sheets. The total number of recognisable lesional 
tumour nuclei was counted in each photograph. Nuclei showing distinct 
immunostaining were counted as positive. The labelling index was calculated as the 
percentage of positive nuclei out of the total number of nuclei counted.  For statistical 
analyses, percentages were grouped as being: 1  = <1%, 2 = 1-5%, 3 = 6-10%, 4=11- 
30%, 5 = 31-50%, 6 = >50%.
Statistical analyses were performed using the Spearman rank correlation test, and the 
Mann-Whitney U non-parametric test for group differences as described in Chapter
2.2.e.
995.3  Results
Immunostaining for PTHrP  and PTH1R was evident only in the cytoplasm of liver 
cells,  tumour  cells  and  bile  ductules.  Pre-absorption  of  the  antibody  with  the 
immunizing peptide  abolished  all  staining for PTHrP.  All  staining  for PTH1R was 
abolished by substitution of normal mouse serum for primary antibody.
5.3.a  Normal Liver
In  all  cases,  hepatocytes  showed  diffuse  weak  staining  for  PTHrP  with  increased 
expression  in  the  hepatocytes  around  central  veins,  and  less  expression  in  the 
hepatocytes around portal veins and tracts [median score 3 (range 2-4)] (Figure 20a). 
In the majority of cases (8 of 10) there was weak patchy staining for PTH1R in the 
hepatocytes, and no staining in 2 cases [median score 1  (range 0-1)]  (Figure 20b). In 
the normal ducts there was  strong staining for PTHrP  [median score 6  (range 4-6)] 
and weak or absent staining for PTH1R [median score 1  (range 0-1)].
5.3.b  Regenerating Nodules
In all the cases of regenerative nodules studied, there was diffuse weak or moderate 
staining for PTHrP  [median score 4  (range 3-6)],  and in 6  of 7 cases  diffuse weak 
staining for PTH1R [median score 3  (range  3-4)]  (Figures 21  a & b).  In the ducts, 
there was predominately strong staining for PTHrP [median score 6 (range 4-9)]), and 
weak or moderate immunostaining for PTH1R [median score 3 (range 1-4)].
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Figure 20 (a)
Figure 20  Im m unohistocheniistry  show ing  weakly  positive  cytoplasm ic  staining 
for  PTHrP  (figure  a)  and  PTH1R (figure  b)  in  hepatocytes  in  a  resection  specim en  of 
normal  human liver
There  is  strong  staining  for  PTHrP  in  normal  ducts  Photographed  at  m agnification 
x50
Figure 20 (b)
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Figure 21  Immunohistocheniistry  showing  positive  cytoplasmic  staining  for 
PTHrP  (figure  a)  and  PTH1R  (figure  b)  in  regenerating  nodules  in  a  resection 
specimen o f cirrhotic liver
Normal  ducts  stain  strongly  for  PTHrP  and  weakly  for  PTH1R  Photographed  at 
magnification x50.
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Figure 21(b)
1025.3.c  Macroregenerative Nodules
In macroregenerative nodules, 5 of 13 cases displayed diffuse weak immunostaining 
for PTHrP,  and the  rest  showed  either diffuse  moderate  intensity  staining  or weak 
with  areas  of stronger  staining  [median  score  4  (range  3-6)]  (Figure  22a).  In  the 
majority of the cases (9 of 13), there was diffuse weak or moderate immunostaining 
for  PTH1R  in  the  nodules,  and  in  the  rest  of the  cases,  weak  patchy  staining  for 
PTH1R [median score 3  (range  1-4)]  (Figure 22b). In the surrounding cirrhotic liver 
there was diffuse weak or moderate staining for PTHrP [median score 3 (range 3-6)] 
and diffusely weak or patchy immunostaining for PTH1R [median score 3  (range  1- 
4)]. In the ducts, there was predominately strong staining for PTHrP [median score 6 
(range 3-6)]), and weak immunostaining for PTH1R [median score 1 (range 1-4)].
5.3.d  Dysplastic Nodules
Six  of the  13  cases  of dysplastic  nodules  showed  diffuse  staining  for  PTHrP  of 
moderate intensity, and 7 showed patchy moderate or weak staining [median score 4 
(range 3-6)]  (Figure 23a). In 5 cases the staining in the nodule was stronger than the 
staining in the surrounding cirrhotic tissue where hepatocytes showed diffusely weak 
or patchy moderate staining for PTHrP  [median score 4 (range 3-6)]. The dysplastic 
nodules showed diffuse or patchy weak staining for PTH1R [median score 1  (range 1- 
4)]  (Figure  23b).  Background  cirrhotic  liver  showed  diffusely  weak  or  patchy 
immunostaining  for PTH1R  [median score  3  (range  1-4)].  In the  ducts,  there was 
predominately strong staining for PTHrP [median score 6 (range 3-9)]), and weak or 
absent immunostaining for PTH1R [median score 1  (range 0-3)].
103Figure 22  Immunohistochemistry  showing  positive  cytoplasmic  staining  for 
PTHrP  (figure  a)  and  PTH1R  (figure  b)  in  a  macroregenerative  nodule  within  a 
resection specimen o f cirrhotic liver containing a macroregenerative nodule
In  adjacent cirrhotic  liver staining for PTHrP  is weaker than  in the macroregenerative 
nodule  Photographed at magnification x 25.
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Figure 23  Immunohistochemistry  showing  positive  cytoplasmic  staining  for 
PTHrP  (figure  a)  and  PTH1R  (figure  b)  in  a  dysplastic  nodule  from  a  resection 
specimen  Photographed at magnification xlOO
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1055.3.e  Hepatocellular Carcinoma
All  20  cases  of HCC  showed  diffusely  positive  staining  for  PTHrP  of moderate 
intensity with areas of stronger intensity [median score 6 (range 4-6)], and staining for 
PTH1R that  was  diffusely  weak  or  of patchy  moderate  intensity  [median  score  3 
(range 1-6)] (Figures 24 a & b). In background liver, immunostaining for PTHrP was 
diffusely weak or moderate [median score 4 (range 1-6)] and staining for PTH1R was 
weak or in one case absent [median score 3 (range 0-3)]. In the ducts, again, there was 
predominately strong staining for PTHrP [median score 6 (range 3-9)]), and weak or 
absent immunostaining for PTH1R [median score 1  (range 0-4)].
106Figure 24  Immunohistochemistry  showing  positive  tumour  cell  staining  for 
PTHrP  (figure  a)  and  PTH1R  (figure  b)  in  a  resection  specimen  of  hepatocellular 
carcinoma
Photographed at magnification x 50.
Figure 24 (b) 
107The mean immunostaining score for PTHrP was highest in the HCC tumour cells and 
then  sequentially  decreased  through  the  dysplastic  nodule  group,  to  the 
macroregenerative nodules, to regenerative nodules to normal heptocytes (Graph  1). 
The intensity of staining  for PTHrP was  significantly  greater in HCC  tumour cells 
compared to  the  intensity of staining  for PTHrP  in dysplastic  nodules  (p  =  0.039), 
macroregenerative nodules (p = 0.007), regenerative nodules (p = 0.001), and normal 
hepatocytes  (p  <  0.001),  and  significantly  greater  in  dysplastic  nodules  and 
macroregenerative nodules compared to normal hepatocytes (p = 0.002 and p = 0.032 
respectively). The difference in immunostaining scores for PTHrP between dysplastic 
nodules  versus  macroregenerative  nodules  and  regenerative  nodules, 
macroregenerative  nodules  versus  regenerative  nodules,  and  regenerative  nodules 
versus normal hepatocytes, was not statistically significant. All of the different tissues 
showed immunopositivity for PTHrP of moderate intensity in the bile ductules. There 
was  no  significant  difference  in  the  ductular  expression  of  PTHrP  between  the 
different tissues. The differences in mean intensity of staining for PTH1R across the 
tissue  groups  were  not  statistically  significant.  There  was  a  significant  positive 
correlation between PTHrP and PTH1R expression across the tissue groups (r = 0.48,
p < 0.001).
108Table 11  Median and mean immunostaining product in non-lesional hepatocytes 
and ducts, and neoplastic cells in thesurgical resection specimen studied.
Non-lesional
hepatocytes
Non-lesional bile 
ducts
Macroregenerative
nodule/dysplastic
nodule/tumour
PTHrP
(0-9)
PTH1R
(0-91_
Ki67
(%)
PTHrP
(0-9)
PTH1R
(0-9)
PTHrP
(0-9)
PTH1R
(0-9)
Ki67
(%)
Normal 
liver 
(n =10)
Median
(range)
3
(2-4)
1
(0-1)
0.1
(0-1)
6
(4-6)
1
(0-1)
Mean 
_  (SD)
3.20
(±0.79)
0.80
(±0.42)
0.1
(±0.32)
5.80
(±0.63)
0.80
(±0.42)
- - -
RN
(n = 7)
Median
(range)
4
(3-6)
3
(3-4)
0.8
(0-5)
6
(4-9)
4
(1-4)
- - -
Mean
(SD)
3.86
(±1.07)
3.14
(±0.38)
1.54
(±1.90)
6.14
(±1.46)
2.71
(±1.25)
- - -
MRN 
(n =13)
Median
(range)
3
(3-6)
3
(1-4)
NA 6
(3-6)
1
(1-4)
4
(3-6)
3
(1-4)
0.98
(0-
11.55)
Mean
(SD)
4.08
(±1.38)
2.54
(±1.20)
NA 5.62
(±0.96)
1.77
(±1.24)
4.46
(±1.33)
2.77
(±1.17)
3.09
(±0.05)
DN 
(n =13)
Median
(range)
4
(3-6)
3
(1-3)
NA 6
(3-9)
1
(0-3)
4
(3-6)
1
(1-4)
3.62
(0-
37.08)
Mean 
.  (SD)
4.31
(±1.03)
2.15
(±0.99)
NA 5.46
(±1.61)
0.92
(±0.73)
4.85
(±1.14)
2.08
(±1.26)
7.57
(±0.09)
HCC 
(n =20)
Median
(range)
4
d-6)
3
(0-4)
NA 6
(3-9)
1
(0-4)
6
(4-6)
3
(1-6)
7.5
(1^0)
Mean
(SD)
4.20
_(±1-61)..
2.20
(±1.15)
NA 5.75
(±1.58)
1.35
(±1.31)
5.60
(±0.82)
3.15
(±1.18)
11.99
(±0.11)
Legend:  RN  =  regenerative  nodules,  MRN  =  macroregenerative  nodules,  DN  = 
dysplastic nodules, HCC = heptocellular carcinoma,  SD = standard deviation, NA = 
not assessed
109Graph 1   Mean intensity of staining for PTHrP and PTH1R in normal liver 
hepatocytes, regenerative nodules (RN), macroregenerative nodules (MRN), 
dysplastic nodules (DN), and hepatocellular carcinoma (HCC) tumour cells.
PTHrP
PTH1R
normal  RN  MRN  DN  HCC
Tissue Section
5.3.6  Expression of Ki67
A progressive increase in Ki67 from regenerative to macroregenerative to dysplastic 
nodules  to  HCC  was  observed  (Figure  25,  Table  11,  Graph  2).  Ki67  scores  were 
significantly  higher  in  dysplastic  nodules  compared  to  regenerative  and 
macroregenerative  nodules  (p =  0.03  and p  =  0.04  respectively),  and  also  in HCC 
compared  to  regenerative  and  regenerative  nodules  (p  =  0.001  and  p  =  0.001 
respectively).  There  was  a low  level  of expression of Ki67  (1%)  in hepatocytes  in 
only one case of normal liver.
There was a positive  correlation between the  Ki67  score  and the  staining index for 
PTHrP (R  =  0.430, p = 0.001, n = 59) and PTH1R ( . R  =  0.324, p = 0.012, n = 59) 
across all tissue groups.
110Figure 25  Immunohistochemistry for Ki67  in resection specimens of normal  liver 
(a),  regenerating  nodules  (b),  macroregenerative  nodule  (c),  dysplastic  nodules  (d), 
and  hepatocellular carcinoma (e &  f)
Positive staining is nuclear and appears as a brown precipitate
* ,v
- ■ ■ M •“ •a i .   s i  -
j   4 '   ‘^ 1   -
Magnification \  50
*  -«r
v . *
°,
Magnification x 50
4T
e *  V  $  i  «;
*  V *  *  ,  >
• *  °
•  »   .V *
.1   f  u  •<?  *
■3  -  ft.
%
P i  9
*  0
*~9ff 
* «
*«
s* *»
1  ° /   < ->
© »  ...
*  * X)  .
k 1
>#
y  \   /•
>*  *■ 
•  9
!  •  %   v  'v   *   ->  •
• . .   •'  •   ■
, ■   •  «  r .  *.
V ;\   ,*
c
.  0
8
4 *•  *  »S,v  • .  f  >
■   a r   *   i
Magnification \   100
o
c
«• '
0
e  *
V
O  
*
/   .  ■   T   •'  *'  ’■   •  *Tk* « V *   '<  •   .
.V  -v  •  - i  ■ .  t  f*4+£k‘l  V  *  *   .   ‘  «   ‘   .
,  •'  '•  *.K>.  *  -  .V  ,
■ *   '/  •   >  *
7  ■'  ■   ;   ••
\   I  ' I   V '  ■   •  .  ■
■   ■   . .  .  \  •   . fft •*’  ■ .  '
*  -X '4   *  4  V   *,-->  •   •  •-  -•*»/"  f J  X   •   Jr.  •   ;
A   :  , .   >   ■ ,  •'  ■   ■
,*V .  '  ,v  ^   ‘  ,  •
• "   '   "   • •
■   V i   '  >  £   v: -  -
; * *  >>''  K   J-4 ■   .V“  ^  .  .'• • •
v"
•A   ■   *•  •'
'*   /•
SL
Ohs®  o
■  v 
••
<-
Magnification \ 50
V   '» I   ^
©A  £>
cl 
— . 6  V
g - ’  ‘ i   v ts '  >
»  " >  #   -   r,  ,*
r  .   4 ^ 1 *   ' V -
V
Magnification x50
f
0   t
;  • .  v   ,(y   *  J
- a   %   •%*,  ^   f<f
Magnification x400Graph 2  Mean Ki67 score in normal liver hepatocytes, regenerative nodules 
(RN), macroregenerative nodules (MRN), dysplastic nodules (DN), and 
hepatocellular carcinoma (HCC) tumour cells.
14
c
t
>
0 *
12
10
4
6
0
2
8
normal  RN MRN DN HCC
Tissue Section
5.4  Conclusions
Immunopositivity for PTHrP was sequentially increased from normal liver, through 
cirrhotic liver and macroregenerative nodules, to dysplastic nodules, with a gradient 
of expression that peaked in malignant cells. This increased expression, supported by 
the positive correlation between PTHrP expression and expression of the proliferation 
marker Ki67, qualifies PTHrP as a likely candidate to influence hepatocyte and 
tumour cell growth. The positive correlation between PTHrP and PTH1R expression 
through the tissue groups supports the possibility of an autocrine/paracrine role for 
PTHrP/PTHIR in the development of regenerative, dysplastic nodules, and HCC.
Similarly, a gradient of increased PTHrP expression through normal to neoplastic and 
carcinomatous tissue has been observed in the prostate. PTHrP is expressed in normal 
prostatic tissue by neuroendocrine cells1  and glandular epithelium. It is also expressed 
in benign prostatic hyperplasia (BPH)cvm  and in epithelial cell cultures derived from 
these tissues," in the premalignant condition prostatic intraepithelial
112neoplasia (PIN),C X C 1 V  and by most prostatic adenocarcinoma.C X C Y ’  cxcvl’cxcvn Protein 
expression has been found to be at higher levels in prostate cancer than in BPHC X C V " or 
normal tissue,C X C V 1  and at significantly higher levels in PIN than in normal prostatic 
epithelium.cxciv PTH1R has been found by both immunohistochemistry and 
polymerase chain reaction to be robustly expressed in the majority of prostatic 
adenocarcinomas studied.cxcvm  In prostate cancer cells PTHrP has been reported to 
play both autocrine/paracrine and intracrine roles, stimulating cell proliferation,cxxxvu’  
cxxxvm  ancj protectjng ceus from apoptotic stimuli.cxcix
There was a low cellular proliferation rate as assessed by Ki67 expression in 
regenerative nodules, with a progressive increase to dysplastic nodules to HCC. This 
is consistent with previous studies showing increased proliferation rates in HCC and 
its precursor lesions.C C ,C C 1 ’ccn The continuous proliferative status of hepatocytes in 
cirrhotic liver is considered to be a facilitating factor for the development of HCC. 
Expression of proliferation markers in cirrhotic liver has been previously described0 0 1 1 1  
and indicates liver cell regeneration occurring in the context of cirrhosis. This 
observation has been followed by studies investigating the possible use of 
proliferation markers to define cirrhotic patients at higher risk of developing HCC.0 0 1 ^ 
oov Borzio et al showed that the hepatocyte proliferation rate, assessed by expression 
of silver-stained nuclear organizer regions (AgNOR), was strongly predictive of 
hepatocellular carcinoma development in the cirrhotic liver. Donato et al, assessing 
liver cell proliferative status by immunostaining for proliferating cell nuclear antigen 
(PCNA) in compensated cirrhotic patients observed that the proliferative rate seemed 
to predict the development of HCC. The low proliferative rate observed in the 
macroregenerative nodules, which are widely regarded to be precursor lesions to 
HCC, has also been previously described,cc’0 0 1  suggesting that their premalignant 
potential is not related to hyperplasticity. There was scanty immunostaining for Ki-67 
in one histologically normal liver sample. This may be because the material was taken 
from the neighbourhood of a colorectal metastasis, and although it consisted of 
morphologically normal liver, some reactive hepatocellular change remains probable.
The positive correlation between PTHrP expression and Ki67 indices in dysplastic 
nodules and HCCs implies that the increased PTHrP expression by dysplastic and 
tumour cells may stimulate cell growth. This finding contradicts the in vitro
113observations of Li et al.c,v They reported that the hepatoma cell line HepG2 secreted 
biologically active PTHrP, which when neutralised by the addition of antiserum to 
PTHrP, increased cell growth. This effect was inhibited by the addition of synthetic 
PTHrP (1-36), and suggested that endogenously secreted PTHrP acted in an 
autocrine/paracrine fashion in HepG2 cells to suppress cell growth. However, this 
human hepatoma cell line is highly differentiated and is well documented to have 
properties that are characteristic of normal hepatocytes,C C V 1 ’ccvn and so their 
observations may represent the effects of endogenous PTHrP in normal liver.
A growth inhibitory effect of N-terminal PTHrP peptides, acting via the 
autocrine/paracrine pathway, mediated by PTH1R, has been seen in the breast cell 
line MCF-7,C C V U 1  and in vascular smooth muscle cells.lxxvn In these examples of 
tumour and physiological cell systems, PTHrP has also been shown to have a 
stimulatory effect independent of PTH1R via the intracrine pathway. In a study by 
Massfelder et al in an aortic vascular cell line, when cells were treated with amino 
terminus-containing peptides cell proliferation was inhibited. By contrast, when the 
same peptides were introduced into the cell by PTHrP transfections that also 
contained the nuclear localisation sequence, cell growth was stimulated. Deletion of 
either of the two localizing signals, PTHrP 88-91 and 102-106, abrogated the effect. 
Thus the overall effect of PTHrP on cell proliferation is dependent upon the net effect 
of the ‘opposing’ inhibitory autocrine/paracrine effects of PTHrP versus the 
stimulatory intracrine effects of PTHrP.
Another study by Massfelder et al in 2001C C 1 X  showed that these paradoxical trophic 
actions of PTHrP in vascular smooth muscle cells are reversed under 
pathophysiological conditions. They studied the effects of PTHrP in renovascular 
smooth muscle cells from normotensive rats (wild type) and spontaneously 
hypertensive rats (SHR). They showed that PTHrP mRNA and protein was increased 
in SHR-derived cells, and that PTH1R transcripts were similar in both cell lines. 
When exogenous PTHrP (1-36) was added to the cells, proliferation of wild type cells 
was decreased, but cell proliferation of SHR cells was increased. Whereas 
transfection with antisense PTHrP (1-139) cDNA, which abolished PTHrP mRNA, 
decreased wild type but increased SHR cell proliferation, i.e. PTHrP via the intracrine 
pathway was stimulating wild type cell proliferation but inhibiting SHR cell
114proliferation. Additional studies by the same group indicated that the preferential 
coupling of PTH1R to G-protein Gi in the SHR cells was responsible for the 
proliferative effect of exogenous PTHrP in these cells. PTHlR-dependent stimulation 
of Gi protein by PTH has previously been shown to decrease activation of adenylyl 
cyclase, and hence the production of cyclic AMP,C C X  which is acknowledged as the 
cellular pathway accounting for the antiproliferative effect of PTHrP in vascular 
smooth muscle cells.lxxvn
It is therefore possible that endogenously secreted PTHrP exerts an antiproliferative 
effect in normal liver, probably via PTH1R. Whereas in regenerating, dysplastic and 
hepatocellular cells, the effect of endogenously secreted PTHrP is to stimulate cell 
proliferation via PTH1R, perhaps by preferentially coupling of the receptor to Gi. In 
this series the average intensity of PTH1R staining rose sharply between normal and 
cirrhotic liver, levelled off or decreased in macroregenerative and dysplastic nodules, 
and increased again in HCCs. The apparent reduction in expression of PTH1R in 
MRNs and DNs may reflect down-regulation of the receptor in response to increased 
levels of presumably endogenous PTHrP interacting with cell surface receptors.
Further in vitro work, studying the effects on cell proliferation of exogenously added 
amino-terminal PTHrP peptides, and the effect of transfection with PTHrP anti-sense 
constructs, are required to define the autocrine and intracrine effects of PTHrP on 
hepatocellular carcinoma cell lines. These studies may then be extended to in vivo 
models to further define the action of PTHrP as a possible regulatory factor for 
hepatocyte growth and differentiation in the normal liver through to HCC.
115Chapter 6  UPTAKE AND CELLULAR PROCESSING OF 
PARATHYROID HORMONE-RELATED PROTEIN
6.1  Introduction
In previous parts of this study, immunoreactive amino-terminal PTHrP was detected 
in the nucleus of some tumour cell lines, and in the tumour cell nucleus in some 
resection specimens of human pancreatic adenocarcinoma. PTH1R was also detected 
by immunohistochemistry in the nucleus of the same resection specimens, and was 
found to be localised to the nucleus in pancreatic adenocarcinoma cell line BxPC3. In 
the majority of cell lines PTH1R was localised to the cytoplasm or cell membrane 
only.
The possible mechanisms by which the secretory protein PTHrP may gain access to 
the cytoplasm after secretion have been previously discussed (Chapter 1.7.a), and may 
involve endocytosis-dependent pathways. Endocytosis of PTH1R, with subsequent 
PTHrP transport and localisation to the nucleus has been demonstrated in some 
studies,lxn’1 x 1 1 1  but others have not supported this concept.lxiv  Although 
immunodetection of PTH1R provides information about expression, and gives an 
indication of localisation of PTH1R protein, it does not give any information about 
functionality of the receptor protein.
The purpose of these experiments was to examine cellular uptake of fluorescently 
labelled exogenous amino-terminal PTHrP (1-34) by the prostatic adenocarcinoma 
cell line PC3, and the hepatocellular carcinoma cell line HepG2. PTHrP (1-34) binds 
to PTH1R with high affinity, and does not contain a nuclear localisation sequence. 
Uptake of labelled PTHrP (1-34) by these PTHlR-expressing cell lines can determine 
whether these cells express PTH1R with a functional binding domain, and 
furthermore examines whether PTHrP (1-34) can gain access to the nucleus via a 
PTH1R endocytosis-dependant pathway.
1166.2  Materials and Methods
6.2.a  Labelling of Peptide
An amino terminal PTHrP (1-34) peptide [Bachem (UK) Ltd., Merseyside, UK] was 
chosen for these experiments because it contains the amino acid sequences required 
for binding and activation of the PTH1R. This peptide was labelled with Alexa Fluor® 
488 (Molecular Probes, Inc, Eugenes, OR, USA), a cadaverine label which is small, 
and water-soluble, with an absorption/emission maxima of ~ 495/519 nm, which can 
be fixed in cells by treatment with formaldehyde or glutaraldehyde.
6.2.b  Removal of Free Dye
Preliminary uptake experiments were performed using labelled peptide that had been 
dialysed in sterile phosphate buffered saline (PBS) for 10 days at 4°C. However, in 
addition to cellular uptake, non-cellular background fluorescence was noted that was 
thought to due to the presence of free dye. For this reason, the labelled peptide was 
further analysed using reverse phase High Performance Liquid Chromatography 
(HPLC) [Beckman Coulter 168 Detector, Beckman Coulter (U.K.) Ltd] measured at 
494nm. This showed 2 peaks: the first at 13 minutes, corresponding to the elution of 
free dye; and a second peak, corresponding to labelled peptide, with an elution time of 
25-27.8 minutes (Figure 26).
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Figure 26  Analysis of PTHrP (1-34) labelled with Alexa Fluor® 488 by reverse 
phase High Performance Liquid Chromatography measured at 494 nm.
Two peaks are observed at 13 and 25-27.8 minutes.
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118Labelled peptide was therefore separated from the labelled peptide/free dye mixture 
by solid-phase extraction using a Sep-Pak C l8 cartridge (Waters Associates, Milford, 
MA, USA). Briefly, prior to use, the Sep-Pak cartridge was rinsed with 5ml of 
aqueous methanol, followed by 5ml of distilled water. The peptide solution was 
passed through the cartridge, which was then flushed with distilled water until all free 
dye had been removed from the cartridge. The absorbed labelled peptide was then 
eluted from the cartridge with 1ml of 60% acetonitrile solution (Sigma-Aldrich 
Corporation, UK). The absorbance of the eluate was measured at 494nm. After 
purification only the later peaks, i.e. 25-27.8 minutes, were remaining. The peak at 13 
minutes had disappeared, indicating that the free dye had been removed (Figure 27). 
Labelled peptide was separated from the 60% acetonitrate-water mixture used for 
elution by speed vacuum. The dry labelled peptide was stored at -20°C, and 
reconstituted with sterile PBS when required.
119Figure 27  Analysis of PTHrP (1 -34) labelled with Alexa Fluor® 488 by reverse 
phase High Performance Liquid Chromatography measured at 494 nm after solid- 
phase extraction of the labelled peptide/free dye mixture.
Peaks at 25-27.8 minutes are observed. The peak previously observed at 13 minutes 
has disappeared, indicating that free dye has been removed and only labelled peptide 
remains.
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1206.2.c  Uptake Experiments
Uptake experiments were performed on PC3 cells and HepG2 cells. Cells were grown 
to 80% confluency in 8 chamber well plates in media containing 10% fetal calf serum 
(FCS). The cells were rinsed in PBS, and then Alexa Fluor labelled PTHrP (1-34), 
diluted in media to a final concentration of 0.02 mg/ml, was added to the cells to be 
incubated at 37°C for 5, 30 or 60 minutes. A negative control containing cells 
incubated in media alone was included in each experiment. The cells were then rinsed 
in PBS, and fixed in buffered formaldehyde for 5 minutes. Nuclei were counterstained 
with 3pg/ml 4',6 diamidino-2-phenylindole (DAPI) for 6 minutes, and mounted using 
Vectashield® mounting medium (Vector Laboratories, Ltd., Peterborough,UK ).The 
slides were examined using a Zeiss Axioscope fluorescence microscope with 
appropriate filters for Alexa Fluor 488 and DAPI fluorescence.
Uptake experiments were repeated with the same concentration of labelled PTHrP (1- 
34) in the presence of excess (0.2mg/ml) unlabelled PTHrP (1-34). This was done in 
order to determine whether the labelled peptide bound specifically to PTH1R, in 
which case its uptake would be reduced or attenuated in the presence of excess 
unlabelled peptide which competitively binds to the same receptor.
6.2.c  Confocal Microscopy
Cellular uptake of labelled PTHrP (1-34) was further examined using confocal 
microscopy (FluoView™ 300 Confocal Microscope, Olympus). Optical sections were 
taken at 0.6-micrometre intervals perpendicular to the Z-axis (microscope optical 
axis) using a dual argon-ion (488 and 514 nanometer; blue/green) laser system.
1216.3  Results
6.3.a  Uptake Experiments of labelled PTHrP (1-34) by PC3 cells
After 5-minute incubation period with labelled peptide there was membranous uptake 
of labelled PTHrP (1-34). After 20-minute and 60-minute incubation periods, there 
was uptake of labelled PTHrP (1-34) to the cytoplasm and nucleus in up to 10% of 
cells (Figure 28). Uptake to these cellular structures was confirmed on confocal 
microscopy. Only minimal background cellular fluorescence was seen in the control 
well.
122Figure 28  Series of confocal  images  representing interval  sections of a  PC3  cell 
after incubation with Alexa Fluor® labelled PTHrP (1-34) for 60 minutes.
The  images in figure (a)  show positive  membranous,  cytoplasmic and  nuclear uptake 
of labelled  PTFlrP  (1-34)  Although  only  12  of the 48  images  collected  through  this 
series are presented in the figure, they represent individual focal planes separated by a 
distance  of approximately  0.6  pm  and  provide  a  good  indication  of the  internal  cell 
structureFigure 28 (b)
The  confocal  image  in  figure  28  (b)  shows  membranous  and  nuclear  uptake  of 
labelled PTHrP (1-34) in a PC3  cellIn the presence of excess unlabelled PTHrP(l-34), there was reduced binding of 
labelled PTHrP(l-34) to the membrane, and no uptake to the cytoplasm or nucleus 
(Figure 29).
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Figure 29  Confocal image of PC'3  cells after incubation with Alexa Fluor labelled
PTHrP (1-34) in the presence of excess unlabelled PTHrP (1-34)
After 20 minutes only  membranous uptake of labelled  PTHrP (1-34)  is seen,  with no 
uptake to the cytoplasm or nucleus6.3.b  Uptake of labelled PTHrP (1-34) by HepG2 cells
Membranous uptake of labelled PTHrP (1-34) was observed after 5- and 20-minute 
incubation periods with labelled peptide. After 60-minute incubation with labelled 
peptide, membranous, cytoplasmic and perinuclear uptake of labelled PTHrP (1-34) 
was seen in up to 5% of cells (Figure 30). Uptake to these cellular structures was 
confirmed on confocal microscopy. Minimal background cellular fluorescence was 
observed in the control well.
Uptake experiments performed in the presence of excess unlabelled PTHrP (1-34), 
reduced binding of labelled PTHrP (1-34) to the membrane, and abolished 
cytoplasmic and perinuclear uptake.
127Figure 30 (a)
Figure 30  Images  taken  with  an  Axioscope  fluorescence  microscope  represent 
uptake  experiments  with  Alexa  Fluor  labelled  PTHrP  (1-34)  on  the  hepatocellular 
carcinoma cell line HepG2
Bound  Alex Fluor 488 labelled PTHrP (1-34) fluoresce green, and the nuclei labelled 
with DAPI fluoresce blue  Images taken from the same representative field have been 
merged  Figure  (a)  shows  membranous  uptake  of labelled  peptide  after  incubation 
with  labelled  PTHrP  (1-34)  for  5  minutes  at  37°C.  Figure  (b)  shows  membranous, 
cytoplasmic,  and  perinuclear uptake of labelled  peptide after a 60-minute  incubation 
with labelled PTHrP (1-34)  Images were captured at x 100 magnification
Figure 30 (b)6.4  Conclusions
In the prostatic adenocarcinoma cell line PC3, fluorescently labelled PTHrP (1-34) 
bound to the cell membrane, was internalised, and subsequently transported to the 
nucleus. Internalisation of PTHrP (1-34) occurred through PTHlR-mediated 
endocytosis, as the presence of excess unlabelled PTHrP (1-34) competed with 
labelled PTHrP (1-34) for occupation and internalisation of available PTH1R, so 
attenuating uptake of labelled PTHrP (1-34). This demonstrated functionality of 
PTH1R in these cells, and suggests that PTH1R mediates not only internalisation of 
PTHrP, but also localisation to the nucleus.
Immunoreactive PTH1R has been demonstrated within the nucleus of various tissues 
in a broad range of cell types.1 ”1  Watson et al identified a nuclear localization 
sequence (NLS) between residues 446 and 473. By transfecting LLC-PK1 porcine 
kidney cells, which do not normally express PTH1R, with a vector containing the 
human wild-type PTH1R gene, they demonstrated that the transgene product entered 
the nucleus. When they transfected a vector containing a gene encoding a PTH1R 
without the NLS, however, the transgene product could only collect in a perinuclear 
ring. Thus, it seems that PTH1R has the ability to go directly to the nucleus, and that 
PTHrP might act on nuclear function through binding to intranuclear PTH1R.
The membranous binding of labelled PTHrP (1-34) to HepG2 cells, with subsequent 
cytoplasmic and perinuclear uptake after a 60-minute interval provides evidence that 
the PTH1R receptors expressed by these cells are also functional, and that PTH1R 
probably mediates PTHrP-endocytosis, but not translocation of PTHrP to the nucleus 
Indeed, amino-terminal PTHrP was not detected immunohistochemically in the 
nucleus in this cell line (chapter 4.3.a.2). It is possible that the PTH1R expressed by 
HepG2 does not contain an NLS, and therefore cannot access the nucleus.
129Chapter 7  CONCLUSIONS AND CLINICAL IMPLICATIONS
These studies utilising immunohistochemistry demonstrate that both PTHrP and 
PTH1R protein are commonly expressed by tumour cells in human adenocarcinoma 
of the pancreas, neuroendocrine tumours of the gastroenteropancreatic axis, and 
hepatocellular carcinoma (HCC). PTHrP and PTH1R protein expression was further 
confirmed by western immunoblotting on cell lysates from different cell lines derived 
from these cancers. PTHrP and PTH1R expression has been documented in a number 
of human tumours, including breast, prostate, colon, and lung cancer. A 
paracrine/autocrine pathway for PTHrP/PTHIR has been reported to exist in these 
tumour systems in which PTHrP/PTHIR has been shown to have a role in neoplastic 
growth and development. The common expression of PTHrP and PTH1R in human 
pancreatic adenocarcinoma, gastroenteropancreatic neuroendocrine tumours, and 
HCC implies that an autocrine/paracrine pathway for PTHrP/PTHIR may exist in 
these tumours, which may also be involved in the regulation of cell growth and 
development.
If PTHrP does influence tumour cell growth, a relationship between the expression of 
PTHrP and cellular proliferation may be observed. This possible relationship was 
studied in hepatocellular carcinoma in chapter 5 using immunohistochemistry in 
resection specimens of human HCC. Cellular proliferation was examined by 
immunostaining for the nuclear proliferation antigen Ki67, and calculating the 
percentage of positive nuclei. PTHrP was measured by a semiquantitative method, 
which scored the intensity of the immunoproduct obtained for PTHrP, and the 
proportion of tumour cells with positive staining. A positive correlation between 
PTHrP staining and Ki67 staining was found (R = 0.49, p = 0.028), implying that 
PTHrP protein expression may influence, or be influenced by, cellular proliferation.
The majority of patients worldwide with HCC have underlying cirrhosis, from any 
cause, which predisposes to HCC.ccxl  Hence cirrhosis can be considered to be a
130premalignant condition. Patients who develop HCC almost always have chronic 
hepatitis, indicating that a chronic necroinflammatory condition is a key element of 
HCC occurrence. The presence of macroregenerative nodules has been evaluated as a 
morphological predictor of HCC in cirrhosis, and this high risk of developing HCC is 
further increased in the presence of high-grade dysplastic nodules.ccxn Up to 50% of 
dysplastic nodules are believed to undergo malignant transformation, and are 
therefore considered as precursor lesions to HCC.
In chapter 5, the expression of PTHrP and PTH1R was further examined in a series of 
resection specimens from normal liver, cirrhotic liver, macroregenerative nodules, 
dysplastic nodules, and hepatocellular carcinoma. Immunostaining was scored by the 
previously described method. A sequential increase in immunostaining for amino- 
terminal PTHrP was observed, from a low level of expression in normal liver, through 
cirrhotic liver and macroregenerative nodules, to dysplastic nodules, with a gradient 
of expression that peaked in malignant cells. This correlated with immunostaining for 
PTH1R across the tissue groups, supporting the existence of an autocrine/paracrine 
pathway for PTHrP/PTHIR in these tissues. The observation that PTHrP is expressed 
in foetal liver, expressed at low levels in adult liver, and then at higher levels 
(‘switched on’) in hepatocellular carcinoma, suggests that in liver, as in a number of 
other tissues, PTHrP may play a role as a regulatory factor for hepatocyte growth and 
differentiation. Immunostaining for the nuclear proliferation antigen Ki67 was also 
examined in these tissues. In regenerative and macroregenerative nodules there was 
low level of expression of Ki67, which increased in dysplastic nodules, with highest 
levels of expression in HCC tumour cells. Across the tissue groups, the gradient of 
PTHrP expression correlated Ki67 staining, suggesting that PTHrP, probably acting 
via PTH1R, is a likely candidate to influence hepatocyte and tumour cell growth.
Estimates from the year 2000 indicate that liver cancer (hepatocellular carcinoma and 
intrahepatic bile duct carcinoma) remains the fifth most common malignancy in men 
and the eighth in women worldwide.ccxm  There is considerable geographical 
variability in the incidence of primary liver cancer, largely explained by the 
distribution and natural history of the hepatitis B and C viruses. However during the 
last two decades, increases of primary liver cancer incidence rates have been reported 
from the United Kingdom,C C X 1 V  Central Europe,ccxv North America,ccxl" Australia, and
131Japan,clxvi accompanied by increases in mortality. The predominant cohort component 
of these increases have been interpreted as a long-term consequence of increased 
hepatitis C virus (HCV) exposures in the period 1960-1970 through contact with 
contaminated blood and intravenous drug use: the passage of 2 to 4 decades 
representing the ‘incubation period’ between HCV infection, and the development of 
cirrhosis and HCC. From this data it is predicted that the number of cases of HCC 
generated by the pool of HCV carriers will continue to increase for some time.
HCC remains a highly fatal cancer. The only curative therapies are surgical resection 
and transplantation. Both of these approaches can be successful, but recurrence of 
HCC is common, and unfortunately the vast majority of patients are not candidates for 
either treatment.  This is often because patients with HCC present late in the course of 
the disease when the tumour is advanced and unresectable, or because they have 
underlying cirrhosis with inadequate hepatic reserve to tolerate extensive resection or 
cytotoxic therapy. Liver transplantation has been successful in treating limited-stage 
HCC, affecting cure on both the tumour and the underlying cirrhosis. However only a 
minority of patients qualify for transplantation, and with the present low availability 
of cadaveric donors, waiting times for transplant are long, leading to inevitable 
disease progression. Because patients at high risk of developing hepatocellular 
carcinoma, i.e. cirrhotic patients from any cause, and patients with chronic hepatitis B 
infection, can be identified, detection of HCC at an early stage by regular surveillance 
is possible and desirable. At present, monitoring of alpha-fetoprotein (AFP) and 
regular ultrasound scanning of the liver at six monthly intervals is recommended for 
cancer surveillance in patients with cirrhosis.C G X V 1  AFP has been used as a serum 
marker for HCC for many years, and has a sensitivity of 39-65%, specificity of 76- 
94%, and a positive predictive value of 9%-50%.ccxvn The poor sensitivity of AFP, 
particularly in the detection of small HCCs, is partly because elevated AFP levels may 
be seen in patients with cirrhosis or chronic hepatitis without HCC. Ultrasonography 
is operator dependent and limited in its ability to differentiate HCC from non­
neoplastic lesions, such as macroregenerative nodules. Combined, AFP and 
ultrasound in general appears to be a more sensitive screening method, however it is 
not known with certainty whether screening with this method is able to reduce all 
cause mortality or HCC mortality. Clearly there is a need for novel strategies for the 
early detection of HCC in high risk patients.
132In chapters 4 and 5, PTHrP protein was found to be expressed by HCC tumour cells in 
all the resection specimens and cell lines tested. There was no significant difference in 
immunostaining obtained for PTHrP between different tumour differentiation types, 
or tumour size (grouped for statistical evaluation into tumours that were < 20mm or > 
20mm), and whether or not there was histological evidence of vascular invasion, local 
invasion or multiple tumours present. PTHrP is undetectable in the circulation of 
normal men and women who are not pregnant, but if it is found to be elevated in the 
serum of patients with HCC, it may be a useful biomarker for HCC screening in high 
risk individuals. Most patients with HCC do not have hypercalcaemia, although 
hypercalcaemia can be expected in up to 10% of patients. Therefore it is likely that if 
PTHrP is detectable in the circulation of patients with HCC, it is present at lower 
levels than observed in patients with humoral hypercalcaemia. Because of the variety 
of molecular forms of PTHrP, linked to its catabolism, its immunoassay is difficult. 
However a number of immunoradiometric assays (IRMA) and radioimmunoassays 
(RIA), recognising the 1-72 and 1-86 domains respectively, are widely used, and have 
been validated in human subjects.C C X V 1 1 1 ’C C X 1 X  If PTHrP is in low abundance in the 
circulation in patients with HCC, the detection limit of the assay used would 
accordingly have to be low. One method available to bypass the difficulty of detecting 
low levels of circulating proteins is the technique of immunodepletion, where the 
most abundant proteins in the serum, such as albumin and immunoglobulins, are 
removed from the serum.ccxx However, this technique would only be reliable if PTHrP 
was not bound to one of these major circulating proteins.
If PTHrP is released by HCC tumour cells into the extracellular compartment, and is 
present in detectable levels in the circulation of patients with HCC, in order to be a 
useful biomarker for screening it must be useful in distinguishing between HCC, and 
patients with cirrhosis or normal liver (Phase 1 study). Therefore serum levels of 
PTHrP in these patients would need to be studied. If significant differences between 
HCC and controls, i.e. patients with cirrhotic or normal liver, are found, a further 
comparison should be made to patients with early HCC [T1 (solitary, < 2 cm, without 
vascular invasion) or T2 (solitary, < 2 cm, with vascular invasion; multiple, one lobe, 
< 2 cm, without vascular invasion; solitary, > 2 cm, without vascular invasion), in 
order to determine its usefulness as a biomarker that can detect early stage cancer.
133Further determinations of the diagnostic capability of PTHrP as a biomarker for early 
stage HCC can then be made in phase 2 studies, which should include enough patients 
to adequately power the study, include controls which are patients for whom 
surveillance will be ultimately applied, i.e. patients with compensated cirrhosis 
without known HCC, and compare the results with currently available screening 
methods (AFP and ultrasonography). They should also estimate true-positive and 
false-positive rates for the clinical assay, and correlate results with covariants such as 
the cause of liver disease, and demographics. If phase 1  or 2 studies show promising 
results, a retrospective longitudinal study to detect preclinical disease (phase 3), 
prospective screening studies (phase 4), and cancer control studies (phase 5) may 
follow.
As a normal healthy cell transforms into a neoplastic cell, normal cellular protein 
expression is altered, and as a consequence, the flow of information by the proteome 
is changed. Altered protein expression is the effect of transcriptional and post 
transcriptional changes, post translational and structural modifications, and changes in 
the subcellular localisation of proteins. A large number of the proteins which are 
dysregulated in HCC undergo post translational alteration. In an analysis of 83 
proteins identified by means of 2-dimensional polyacrylamide gel electrophoresis (2- 
D PAGE)1  and mass spectroscopy, in HCC tissue, only 30% of protein changes 
correlated with changes at the corresponding transcript level, and notably 33% of 
proteins identified as modified in HCC corresponded to posttranslational protein 
cleavages.ccxxl Some of the proteolytic fragments generated were released into the 
extracellular compartment, and were detected in the sera of patients with HCC. 
Protein-processing dysregulation of PTHrP may occur which is specific to HCC. This 
may generate specific isoforms of PTHrP, and cleavage products in particular. This 
possibility could be further evaluated by analysis of HCC tissue using 2-D PAGE, 
followed by protein identification using mass spectroscopy. This may identify PTHrP 
species that could act as novel biological markers discriminating between HCC and 
other liver diseases that express PTHrP at lower levels, i.e. cirrhotic liver, 
macroregenerative and dysplastic nodules. However to be clinically useful, the 
candidate marker would have to be detectable in biological fluids such as plasma,
1  This separates proteins first according to their isoelectric point, and then submits them to a second 
separation in relation to their mass.
134serum and urine. If HCC does predominately generate and release into the circulation 
PTHrP isoforms that cannot activate PTH1R, or cleavage products of PTHrP that do 
not contain the amino-terminus, this may explain why humoral hypercalcaemia is not 
frequently seen in patients with HCC.
Because the majority of patients with HCC are not candidates for curative resection or 
liver transplantation, and current chemotherapy agents are largely ineffective and too 
toxic for these patients who usually have underlying cirrhosis, most therapeutic 
techniques are local ablative therapies, the development of which has recently 
undergone great progress. These techniques include chemoembolisation,C 0xxl1’ccxxln 
percutaneous injection of ethanol,C C X X 1 V  radiofrequency ablation,ccxxv focused 
ultrasound ablation,ccxxvl and intrahepatic infusion of ytrium-90 microspheres.C G X X v n  
However, although ablative therapies may slow the progression of cancer and prolong 
survival, they are unlikely to lead to cures or long-term remission in disease. 
Therefore new non-cytotoxic agents are need for HCC. A number of phase II trails 
have recently been published, reporting a growth-inhibitory effect of vitamin D 
analogues, administered either orally or directly with lipiodol via the hepatic artery in 
patients with inoperable HCC.ccxxv,11’ccxxlx  Dalhoff K et al reported  the results of an 
uncontrolled study of oral seocalcitol, a vitamin D analogue, given to 56 patients with 
inoperable advanced HCC. The dose was titrated according to serum calcium levels, 
and treatment effect was evaluated by regular CT scans. Out of 33 patients evaluable 
for tumour response, two had complete response (CR), 12 stable disease and 19 
progressive disease. The CRs appeared after 6 and 24 months of treatment, and lasted 
for 29 and at least 36 months (one patient was still in remission when the data 
censored). Seocalcitol was well tolerated; the most frequently reported toxicity being 
hypercalcaemia, with associated symptoms. Any survival benefit with or without 
tumour response is still to be determined with controlled trials.
The vitamin D nuclear receptor is expressed in hepatocytes0 C X X X  and, more abundantly, 
in HCC cells. A number of vitamin D analogues have been shown to induce 
differentiation and inhibit tumour growth in hepatocellular carcinoma animal models 
and in HCC cell lines.ccxxxl Vitamin D has been shown to down-regulate the 
expression of PTHrP mRNA and secreted protein levels via a transcriptional system 
in the human prostate adenocarcinoma cell line PC3.ccxxxn Vitamin D3 has also been
135shown to down-regulate PTH1R gene expression in a cell specific manner.ccxxxin  The 
observed growth-inhibitory effects of vitamin D analogues in hepatocellular 
carcinoma may involve inhibition of PTHrP/PTHIR expression by this hormone. This 
possibility could be investigated further by in vitro studies of the effect of vitamin D 
analogues on PTHrP/PTHIR mRNA and protein expression in HCC cell lines. 
Vitamin D analogues may have a therapeutic role in the treatment of HCC, and 
maintaining adequate plasma levels of vitamin D may be beneficial in the prevention 
and control of these tumours.
Pancreatic cancer also has a very high mortality, with an overall five-year survival of 
less than five percent, and is the fifth leading cause of death from cancer in the 
western world. The incidence of pancreatic cancer has steadily increased over the past 
decades. The UK has an especially high incidence of 10-12 per 100,000 population 
per year, with around 7,000 deaths per year. The reason for this high mortality is that 
these cancers often produce little in the way of symptoms until they are advanced and 
unamenable to curative surgical resection. Adenocarcinomas of the pancreas also 
disseminate early, show aggressive local tumour progression, and are resistant to 
treatment with chemotherapy and radiation.
Identification of patients with early pancreatic cancer should increase five-year 
survival. Patients with idiopathic and alcoholic pancreatitis, and new-onset diabetes 
mellitus (less than two years, no family history, age greater than fifty years) have a 
low, but increased risk of having or developing pancreatic cancer. Patients with 
hereditary pancreatitis who are older than forty-five years and have a paternal pattern 
of inheritance (estimated cumulative incidence to age seventy is approximately 
seventy-five percent),C C X X X 1 V  intraductal papillary mucinous tumour (IPMT),C C X X X V  
familial pancreatic cancer, and pancreatic masses, have a high risk of developing 
pancreatic cancer. Ideally these patients should be carefully evaluated for pancreatic 
cancer.  Unfortunately however, screening strategies for the detection of pancreatic 
cancer have been hampered by the low sensitivity of the currently available tumour 
marker Ca 19-9 in small stage 1 tumours, and the comparative lack of sensitivity of 
available radiological imaging. At present the most sensitive imaging test is 
endoscopic ultrasound (EUS),C C X X X V 1  however its sensitivity for detection of early 
pancreatic cancer is unknown, and it is still not widely available in the UK. The
136sensitivity of Cal9-9 is between 70-86%,'ccxxxv,1’ccxxxvin depending upon cut-off levels, 
with a specificity of 87%. However, biliary obstruction with cholangitis caused by a 
lesion other than cancer also causes high serum levels of Ca 19-9.C C X X X 1 X  Currently the 
best that can be offered to patients at high risk of developing adenocarcinoma of the 
pancreas is spiral computed tomography (CT), followed by EUS if the CT results are 
undiagnostic, and measurement of Cal9-9.
In chapter 2, PTHrP was found to be expressed by tumour cells in the majority of 
resection specimens of human pancreatic adenocarcinoma, and in all human 
pancreatic carcinoma cell lines tested. If PTHrP is released by tumour cells into the 
extracellular compartment of patients with adenocarcinoma of the pancreas, and is 
present in detectable levels in serum, plasma or urine, it may be a useful tumour 
marker in these patients, particularly if it is produced at detectable levels in early 
stage 1 tumours. Again, in order to be a useful biomarker for screening it must be 
useful in distinguishing between pancreatic cancer and patients with chronic 
pancreatitis, normal pancreas, and from patients with cholangitis and biliary 
obstruction from benign pathology. Bouvet et al developed an orthotopic mouse 
model of the PTHrP-producing human pancreatic cell line, BxPC3, which had been 
transduced with green fluorescence protein so that tumour growth and metastases 
could be easily visualised. Serum PTHrP was measured by immunoassay at 5 and 13 
weeks after tumour implantation, and was found to correlate with tumour burden, 
indicating that PTHrP could serve as a tumour marker in an animal model of 
pancreatic cancer.ccxl
Alternatively, protein-processing dysregulation of PTHrP may occur which is specific 
to pancreatic adenocarcinoma, generating specific isoforms and cleavage products of 
PTHrP. This possibility may be further evaluated, initially by analysis of pancreatic 
adenocarcinoma tissue using proteonomic techniques, such as 2-D PAGE followed by 
mass spectroscopy, multidimensional protein identification technology,  surface-
2 This technique combines enzymatic digestion of complex protein mixtures, separation of the 
generated peptides by liquid chromatography, and then further analysis of the peptides by mass 
spectroscopy analysis. An advantage of this technique is the detection of low abundance protein, 
however a major limitation is the loss of information of potential modifications of the original protein.
137enhanced laser desorption ionization (SELDI),3 and protein microarray.4, C C X X 1  This 
may isolate PTHrP species that may become new biological markers that could 
discriminate between pancreatic adenocarcinoma and other tumours that produce 
PTHrP. The candidate marker would have to be detectable in biological fluids to be 
useful clinically.
PTHrP was also found to be strongly expressed by gastroenteropancreatic 
neuroendocrine tumours (chapter 3). If detected in the circulation in this group of 
patients, it may also be a potentially useful tumour marker. The glycoprotein 
chromogranin A (CgA), which is found in the storage granules of neuroendocrine 
cells and released during exocytosis, is currently used and is considered the most 
reliable serum marker for these tumours. Assays for its measurement in serum are 
established and widely available. Reported sensitivities for CgA in the detection of 
gastroenteropancreatic endocrine tumours are 84-92%.ccxh’ccxln CgA sensitivity is 
higher for functioning compared to non-functioning tumours (96% versus 75%), and 
is higher in gastrointestinal versus pancreatic endocrine tumours (91% versus 
74%).ccxl,v Elevated levels of CgA are strongly correlated with tumour volume,ccxhn 
and are reliable markers in the follow-up of disease. Therefore there is less clinical 
need for novel tumour markers for these tumours. However used in combination with 
CgA, serum PTHrP may increase the sensitivity in the diagnosis of 
gastroenteropancreatic neuroendocrine tumours, particularly of non-functioning 
pancreatic endocrine tumours.
3 SELDI technology is based on the selective retention of proteins on modified array surfaces, and 
requires relatively small amounts of material. Unbound proteins are discarded, and retained proteins are 
analysed by mass spectroscopy, generating a specific profile of the analysed proteome. Proteome 
profiles are then compared, and statistically significant differences in protein expression among 
different samples are deciphered. A major limitation of this technique is that individual proteins are not 
usually identified.
4 Two protein microarray formats exist. The first involves high-density immobilisation arrays of 
antibodies. Bound proteins are detected by molecular tags. Limitations of this technique include the 
lack of availability of suitable binding molecules that can cope with protein diversity, and the fact that 
recognition molecules will profile binding epitopes rather than functional proteins, and may not 
discriminate between processed isoforms. A second format is reverse-phase protein microarray, where 
protein mixtures are arrayed and probed with a specific antibody, allowing semiquantification of the 
protein. Specific proteins (issued from complementary DNA expression libraries, phage display 
libraries, or protein fractionation) may be captured on the array, allowing the detection of 
autoantibodies in human serum.
138For most patients with advanced hepatocellular carcinoma, pancreatic 
adenocarcinoma, or gastroenteropancreatic neuroendocrine tumours, treatment 
options are limited, resulting in a poor prognosis. Novel treatment strategies are 
therefore urgently required. A targeted therapy such as gene therapy is an example of 
a new strategy in cancer treatment. For gene therapy, delivery systems (viral or 
nonviral vectors) are used to introduce DNA contructs into living cells, in which the 
therapeutic gene products are expressed. For the treatment of malignant tumours, the 
reintroduction of tumour suppressor genes, expression of suicide genes rendering cells 
sensitive to chemotherapeutic agents, and expression of genes that block 
angiogenesis, are all possible approaches. However the problem lies in cell specific 
delivery of genes to tumour cells. Targeting gene therapy to tumour cells by the use of 
monoclonal antibodies that are specific to tumour cell surface antigens may result 
both in enhanced uptake of the delivery system and reduced toxicity, because targeted 
delivery systems will not damage normal cells not expressing the antigen. Antigen- 
specific antibodies may also be conjugated to chemotherapeutic agents such as 
methotrexate, and cytotoxic peptides to produce antitumour effects.ccxhv  In this 
respect, PTHrP is an unsuitable target for this type of antibody-directed therapy, as it 
is also expressed by some normal tissues.
The development of humanized monoclonal antibodies against PTHrP may however 
have a role in the management of humoral hypercalcaemia of malignancy (HHM). A 
humanized antibody which specifically recognises PTHrP (1-34) and neutralizes 
PTHrP functions in vivo and vitro was administered intravenously into HHM mouse 
models bearing human pancreatic cancer and lung cancer xenografts. The human anti- 
PTHrP antibody normalized blood calcium levels. The animals also showed an 
improvement in body weight, food consumption, water intake, and renal function. 
These results demonstrated that PTHrP is a major pathogenic factor of hypercalcemia 
and cachexia in these animals, and suggested that the humanized anti-PTHrP antibody 
may be an effective and beneficial agent for patients with HHM.ccxlv’ccxlvl
Peptide receptor-targeted therapy is an alternative approach. This utilises knowledge 
of the expression of particular peptide receptors on tumour cells, and identifies small 
peptides that bind to active sites of the receptor. Random phage peptide display 
libraries have been widely used to identify such peptides that mimic epitopes
139recognised by antibodies, and are now finding increasing application in the 
identification of small peptides that bind to active sites of other molecules, including 
receptors and enzymes. Such peptides may provide novel ligands for targeting tumour 
cells, and may be labelled with either diagnostic radionuclide tracers in order to 
accurately diagnose disease, or therapeutic radionuclide isotopes in order to treat 
disease. Alternatively these peptides could be linked to chemotherapeutic agents that 
are directly targeted to the tumour cells, or provide receptor antagonists, partial 
agonists, or agonists that down-regulate constitutive expression of the receptor.
In this study, PTHrP was localised to the nucleus in the following tumour cell lines: 
human prostatic adenocarcinoma PC3, human pancreatic adenocarcinoma BxPC3, rat 
buffalo hepatoma MCA RH 7777, and rat islet cell tumour CRI-G1. Furthermore, in 
PC3 cells, fluorescently labelled PTHrP (1-34) was internalised, transported and 
localized to the nucleus. Uptake of labelled peptide was attenuated by competition 
with unlabelled PTHrP (1-34), and therefore cellular uptake probably occurred 
through PTHlR-mediated endocytosis. Targeting PTH1R may therefore be an 
effective vehicle to the tumour cell cytoplasm and nucleus for the delivery of 
radionuclide isotopes, chemotherapy, or gene therapy. The expression of PTH1R by 
many normal tissues, however, as well as by tumour cells means that targeting this 
receptor with such agents is likely to cause intolerable toxicity. Another approach 
would be to deliver an agent that is expressed in normal cells, but is down-regulated 
by tumour cells. For example, the expression of a recently cloned P-galactosidase 
binding protein, galectin-8, whose function is to reduce cell migration, is decreased 
markedly during tumorigenesis in human colon tissue, and is expressed at a much 
lower level than in normal colonic tissue or in benign colonic tumours.ccxlvn Transfer 
of galectin-8 to tumour cells, may therefore be an appropriate therapeutic strategy to 
suppress tumour cell migration and metastases.
Alternatively, PTH1R isoforms may exist that are tumour specific, i.e. are not 
expressed by normal tissue. This phenomenon has been described for other G-protein- 
coupled peptide receptors such as the cholecystokinin 2 receptor (CCK-2R), whose 
natural ligand is gastrin, which is expressed by normal gastric glands and in wide 
spread areas of the brain, such as the cerebral cortex and limbic structures, and in 
gastrointestinal tumours such as colorectal cancers, pancreatic cancer and
140hepatocellular carcinoma. A number of splice variants of the CCK-2R have been 
described, including a CCK-2R with a retained intron IV (CCK-2iIVsv). This splice 
variant, which appears to be constitutively active, is expressed very poorly in normal 
colorectal mucosa, but highly expressed in colorectal primary tumours and liver 
metastases. A stepwise increase in its expression is observed during the progression 
from premalignant Barrett’s metaplasia to oesophageal carcinoma.ccxlvin The so-called 
‘truncated’ PTH1R receptor detected as a 45kDa band by western immunoblotting of 
lysates from the prostate cancer cell line PC3, and the pancreatic adenocarcinoma cell 
lines, AR42J and Panc-1, may also represent a splice variant form of PTH1R. If this is 
a variant form of PTH1R, and is a functional receptor which is highly expressed by 
these tumour cells, but expressed at low levels, or not at all in normal cells, it may be 
a suitable target for receptor-targeted therapy of these tumours. This possibility should 
be further explored.
A third innovative avenue for targeting these resistant tumours is via 
immunotherapeutic strategies. Vaccines have been developed to target peptides 
involved in tumour autocrine pathways, such as the anti-gastrin vaccine, INSEGIA™ 
(Aphton Corporation, CA, USA), which neutralises amidated gastrin 17 and glycine- 
extended gastrin 17. Gastrin 17 is a growth factor for pancreatic, gastric and 
colorectal cancers. Phase 2 studies in patients with advanced pancreatic and gastric 
adenocarcinomas, have shown that the vaccine was well tolerated, produced adequate 
antibody responses in the majority of patients, and prolonged survival in pancreatic 
cancer patients.ccxhx’ccl
An autocrine pathway involving PTHrP/PTHIR has been documented in some 
tumour systems, where PTHrP has been shown to have a growth regulating effect. 
These studies have suggested that such a pathway also exists in adenocarcinoma of 
the pancreas, gastroenteropancreatic neuroendocrine tumours, and HCC. In 
gastroenteropancreatic neuroendocrine tumours, PTHrP may have an inhibitory effect 
on cell growth, and in HCC, PTHrP appears to promote cell growth. Therefore in 
HCC at least, PTHrP may be an appropriate target for this type of immunotherapy 
strategy, using a synthetic PTHrP peptide corresponding to the sequence involved in 
receptor binding and activation [PTHrP (1-34)] bound to a carrier molecule, to
141generate an immune response against PTHrP, preventing its interaction with tumour 
cells. Such a strategy may also have a role in the management of patients with HHM.
An active immunisation approach has been used in patients in the treatment of 
hypercalcaemia due to parathyroid hormone secretion by parathyroid carcinoma. 
These tumours are highly differentiated and slow growing with a clinical course of 
years. Symptoms and death are the result of the metabolic actions of parathyroid 
hormone on PTH1R. Bradwell et al used human and bovine PTH peptide antigens 
synthesised on lysine webs as multiantigenic peptides mixed with Freund’s complete 
adjuvant, in order to break self-tolerance (B-cell tolerance) and induce a strong 
immune response. An adequate antibody response to PTH was produced, with a 
corresponding reduction in serum calcium levels, accompanied by a marked clinical 
improvement.0 0 1 1  A successful anti-PTHrP vaccine may also have a beneficial effect 
against the symptoms of cancer-associated cachexia. PTHrP has recently been 
recognised as a procachectic factor; elevated serum levels of PTHrP are associated 
with the proinflammatory and cachectogenic serum cytokines tumour necrosis factor- 
alpha and interleukin-6.0 0 1 1 1 ’0 1
This thesis has demonstrated that PTHrP and PTH1R are commonly expressed by 
tumour cells in human adenocarcinoma of the pancreas, gastroenteropancreatic 
neuroendocrine tumours, and hepatocellular carcinoma. The expression of both 
PTHrP protein and its corresponding receptor, PTH1R, suggests a possible 
autocrine/paracrine role for PTHrP/PTHIR in these tumours. In human HCC 
resection specimens, a positive correlation between PTHrP staining and staining for 
the nuclear proliferation antigen Ki67 was found, implying that PTHrP protein 
expression may influence, or be influenced by cellular proliferation in HCC. 
Furthermore, low level PTHrP staining was observed in normal liver resection 
specimens, followed by an observed sequential increase in PTHrP staining through 
cirrhotic liver, in which HCC normally arises, to the putative precursor lesions to 
HCC, macroregenerative nodules and dysplastic nodules, with a gradient of 
expression that peaked in malignant cells. This correlated with immunostaining for 
PTH1R across the tissue groups, supporting the existence of an autocrine/paracrine 
pathway for PTHrP/PTHIR in these tissues. Immunostaining for Ki67 was also
142increased, from a low level of expression in cirrhotic liver and macroregenerative 
nodules, to an increased level in dysplastic nodules, with highest levels in HCC 
tumour cells. The gradient of PTHrP expression correlated Ki67 staining, suggesting 
that PTHrP, probably acting via PTH1R, is a likely candidate to influence hepatocyte 
and tumour cell growth.
If PTHrP, its isoforms, or cleavage products, are detectable in the circulation of 
patients with these tumours, they may be useful serum tumour markers. For pancreatic 
adenocarcinoma and HCC in particular, there is a clinical need for new biomarkers, in 
order to facilitate early tumour diagnosis at a stage when curative resection is 
possible, and to provide an effective screening tool in patients at high risk of 
developing these tumours. Once the pathophysiological role of PTHrP/PTHIR in 
human adenocarcinoma of the pancreas, hepatocellular carcinoma, and 
gastroenteropancreatic neuroendocrine tumours is better understood, agents that target 
this system, including novel receptor-targeted therapies and immunotherapeutic 
strategies, may have a therapeutic role in these often refractory tumours in which new 
agents for clinical evaluation remains a high priority.
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155APPENDICES
Appendix I
Background information on F423-1 ascites fluid lot P2405Q1
A.  Peptide
The  PTHrP  immunomimic  consisted  of the  10  amino  terminal  amino  acids  (N- 
terminal):  PTHrP  (l-lO)-spacer (= N-terminal):  Ala-Val-Ser-Glu-His-Gln-Leu-Leu- 
His-Asn-Ser-Ser-Cvs. M.W. 1425.56.
B.  Conjugate
The peptide was conjugated to diphtheria toxoid (“DT”) following Aphton’s standard 
laboratory coupling method.  EMCS was used as the cross linking agent.  The final 
substitution  ratios  per  105  molecular  weight  DT  were  9.2.  The  conjugate  was 
lyophilized.
C.  Immunogen
The conjugate was formulated as water in oil emulsion using montanide ISA 703 as a 
vehicle  in  a  70:30  (oil:water)  weight/weight  ratio  (conjugate  concentration  1.0 
mg/ml).  The  emulsions were prepared by a hand mixing technique.  The emulsion 
was used to immunize mice.
D.  Immunogenicity/Assays
Female CAF1/J mice were immunized with the emulsion at a dose of 100 pg in 0.1 
ml, given intraperitonially.  Five mice were immunized with the conjugate. The mice 
were injected on days 0,  14 and 28 and bled on days 0 and 28.
Serum anti-PTHrP antibody levels were determined in the mouse serum by enzyme- 
linked-immunosorbent-assay (“ELISA”).
156A solid phase ELISA was developed to measure anti-PTHrP antibody in the sera.  The 
target antigen for direct binding ELISA was PTHrP (1-40) (Sigma-Aldrich, Inc, UK).
E.  Hybridoma
Monoclonal antibody against PTHrP would be suitable for diagnostic and therapeutic 
applications.  In order to obtain a monoclonal antibody specific against the PTHrP (1- 
10) peptide, a cell fusion was performed.
P3/NS-1  (non-secreting myeloma, mouse) cells were fused with spleen cells  from a 
CAF1/J mouse that was immunized with PTHrP(l-10)-spacer-DTc conjugate.  Four 
days  prior  to  cell  fusion,  the  mice  received  an  aqueous  boost  of  0.1  mg 
conjugate/mouse.  The method used for the cell fusion and hybridoma production was 
similar  to  the  protocol  in  Selected  Methods  in  Immunology0 0 1 ".  Clones producing 
anti-PTHrP  antibody  were  selected  by  ELISA,  with  PTHrP  (1-40)  as  the  target 
antigen  and  inhibited  with  PTHrP  (1-10)  epitope  peptide.  Alkaline  phosphatase 
conjugated rabbit anti-mouse IgG+A+M (H+L) antibody was used as the developing 
reagent.  Four final hybridoma lines were selected and named F423-1, F423-2, F423-3 
and  F423-4.  The  isotype  of lines  F423-1  to  F423-3  were  IgGl  and  F423-4  was 
IgG2b.  Line F423-1  gave the highest binding by ELISA and the highest inhibition by 
PTHrP (1-10) epitope peptide (94%); while the 3 other lines gave comparable values, 
with line F423-4 being the lowest antibody producer.
F423-1, anti-PTHrP (T-10I Ascites in Balb/CJ mice Lot P240501
PURPOSE:  to produce F423-1  mouse ascites fluid, anti-PTHrP(l-lO) IgGl  MAb in 
6 Balb/CJ female mice primed with Pristane.
MATERIALS:
■   Fusion # 423-1 (anti-PTHrP (l-lO)-DTc) MAb cell line
■   6  Balb/CJ  female  mice,  retired breeders  from  Jackson  Labs  (Davis,  CA,  USA) 
(date of birth: 05/00, received 02/07/01)
•  Pristane (Sigma)
157■   Sterile PBS.
■   Sorvall®  RC-5B  refrigerated  superspeed  centrifuge  (Dupont,  DE,  USA),  with 
Sorvall® SS-34 rotor, angular velocity setting of 10 revolutions/minute (RPM) x 
1000.  Aphton equipment # EQ003 8.
■   Glass syringe filter (Gelman Sciences, MI, USA)
■   Whatman® filter papers (Whatman Inc, NJ, USA):  # 1, # 3 and # 5 (2.5 pm)
■   0.22 pm cellulose acetate, 150 ml Tube Top filter (Coming, NY, USA).
METHOD:
14-Mar-01 (Day -19). Priming mice with Pristane
1.  Six mice were injected with 0.5 ml/mouse of Pristane using a 21  & 23G needle by 
first going under subcutaneous tissue for approximately half a centimeter and then 
intraperitoneally to avoid oil leakage.
2-Ayr-Ol (Day 0), Injection 1 of mice with fusion cells
2.  Cells were harvested from T-flasks (T-75 & T-25) into a 50 ml centrifuge tube (47 
ml cells).
3.  Cells were centrifuged at 400 g for 10 minutes at room temperature.
4.  Supernatant was collected and saved.  The centrifuge tube was gently tapped to 
break the cell pellet to which PBS was added and then mixed well.
5.  Viable cells were counted using a haemocytometer.
6.  All six mice were injected intraperitoneally with 4 x 106 cells/mouse.
Ascites tap on different days
Mice were tapped  for ascites,  which was  spun with high speed centrifuge at  10000
RPM for 30 minutes, collected, and stored frozen until ready to use.
25-May-01, ascites pool/filtration
1.  All the ascites was thawed.
2.  Fatty clots were removed and the fluid was pooled.
1583.  In  a  laminar  flow-hood,  the  fluid was  filtered using  a Glass  Acrodisc,  and with 
Whatman® filter papers in an Erlenmeyer flask.  The filtration process was repeated 
with decreasing membrane size filters until most of the fat was removed.  For the final 
sterile filtration, a 150 ml bottle top 0.22 pm CA filter with filter paper was used.
4.  The  final  38 ml  (19 ml x  2 vials;  0.6 ml x  1  vial  for assays)  lot was named as 
P240501,  and stored -20°C in a chest freezer (later moved into the lab REVCO at - 
70°C).
159Appendix II
Anti-PTHrP
A novel monoclonal antibody specific to PTHrP was raised in a mouse to the first 10 
amino terminal amino acids of human PTHrP (amino acids 1-10) (kindly provided by 
Aphton Corporation, Woodland, USA). This antibody is specific to human and rat 
PTHrP, and does not show any cross-reactivity with PTH (Appendix I).
The specificity of staining of the antibody was initially established on the following 
cases: regenerating liver, where there was cytoplasmic staining of the proliferating 
bile ductules, as previously described0 0 1 1 1  (Figure la); and cases of breast carcinoma, 
where there was cytoplasmic staining of tumour cells, which is also well documented 
in the majority of tumours.ccln  Negative control sections were obtained by omitting 
the primary antibody. The specificity of positive staining was determined by pre­
absorbing the same concentration of antibody with an excess concentration of the 
immunizing peptide overnight at 4°C. When the antibody-antigen solution was 
applied to serial tissue sections adjacent to the antibody-treated sections, staining was 
completely abolished (Figure lb).
After optimisation experiments on control tissue, a dilution of 1  in 1000 in tris 
buffered saline (TBS) was selected for use on the test tissues. Antigenic unmasking 
was carried out by pressure cooking the slides at 115°C in 0.1 M citrate buffer, pH 
6.0, for 90 seconds.
160Anti-PTHIR
PTH1R expression was detected using a commercially available mouse monoclonal 
anti-PTHIR antibody (Clone 3D1.1) (Labvision Corporation, USA), raised against an 
epitope located in amino acids 146-169 of the human PTH/PTHrP receptor (PTH1R). 
PTH1R has previously been shown to be expressed in human breast 
adenocarcinoma,ccln and therefore a well-characterised case of human breast 
adenocarcinoma was selected for use as a control in which cytoplasmic staining was 
seen. A case of regenerating liver was also tested with the antibody, and positive 
staining was found in the bile ductules (Figure lc).
After optimization experiments on the control tissue, a primary antibody dilution of 1  
in 50 in TBS was used in subsequent experiments. Antigenic unmasking was 
performed by microwaving the slides in 0.1 M citrate buffer, pH 6.0, for 20 minutes.
161I  igure  1   (u)
Figure  1   Inimunohistochemistry of PTHrP (1-10) (a) and PTH1R (c) on sections 
of regenerating liver
Positive cytoplasmic staining of the bile ductules appears as a red precipitate  Staining 
for  PTHrP (1-10)  is abolished  by  preabsorption of the  antibody with peptide (Figure 
b)  Images photographed at magnification x  100
I  igure  1 (h )
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The APAAP method
Endogenous alkaline phosphatase activity was blocked by incubation in 15% acetic 
acid for 20 minutes. To unmask antigenic binding sites, slides were then heated in 0.1 
M citrate buffer, pH 6.0, before being allowed to cool to room temperature. In order 
to block non-specific binding of the secondary antibody, the slides were incubated in 
10% normal rabbit serum (DakoCytomation, Ely, UK) in tris-buffered saline (TBS) 
for 20 minutes. The slides were then incubated with the primary antibody for 1  hour at 
room temperature. Rabbit anti-mouse immunoglobulin (DakoCytomation, Ely, UK) at 
a dilution of 1  in 50 in TBS, with 1  in 25 dilution of normal human serum, was 
applied for 30 minutes and then collected. The tertiary antibody, mouse monoclonal 
alkaline phosphatase anti-alkaline phosphatase (APAAP) at a dilution of 1  in 40 in 
TBS was applied for 30 minutes and then collected. These antibodies were then 
sequentially reapplied for 20 minutes each. During each step, the slides were rinsed in 
TBS for 5 minutes. Positive staining was visualised using Fast Red (Sigma) as 
chromogen, incubating at room temperature for 10-20 minutes. Nuclei were 
counterstained with Meyer’s haematoxylin, and the slides were air dried and mounted 
in Loctite UV (Loctite, UK) adhesive.
The ABC method
The slides were incubated with 0.5% hydrogen peroxide in methanol for 10 minutes. 
For the detection of the Ki67 antigen, antigenic unmasking was carried out by 
pressure cooking the slides at 115°C in 0.1 M citrate buffer, pH 6.0, for 135 seconds. 
In order to block non-specific binding of the secondary antibody, the slides were 
incubated in 10% normal goat serum (Dako) in TBS for 20 minutes, and then 
incubated with the primary antibody for 1  hour at room temperature. After rinsing 
with TBS, the sections were incubated for 30 minutes with biotinylated affinity- 
purified goat antibody to mouse/rabbit immunoglobulins (Dako) (diluted to 1  in 100 
in TBS, with 1 in 25 dilution of normal human serum). After a further 5 minute rinse 
in TBS, the sections were incubated with streptavidin (Dako) (1 in 100 dilution in 
TBS) and biotinylated horseradish peroxidase (Dako) (1 in 100 dilution in TBS,
164prepared 30 minutes before application) for 30 minutes. After a final rinse in TBS, the 
sections were incubated with the prepared chromogenic substrate solution for 
peroxidase, DAB (Vector Laboratories Ltd, UK), for 10 minutes. Slides were rinsed 
in distilled water and counterstained with Meyer’s haematoxylin. Slides were then 
dehydrated through alcohol and xylene, and mounted.
165